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ABSTRACT 
 
Laryngotracheal disorders resulting in airway obstruction, although rare, can 
cause significant morbidity and can be life threatening.  Current treatments include 
augmenting the airway with the patient’s own rib cartilage.  Specialized surgical 
technique and an invasive, multi-site surgery are required for this procedure.  Thus, 
an off-the-shelf tissue-engineered product is needed that would replace the need for 
autologous tissue and eliminate the challenges for the surgeon and patient.  The 
tissue-engineering approach of “scaffold, cells, signals” was used to design a fibrous, 
graded bilayer scaffold with one layer providing long-term structural support (i.e., 
polycaprolactone (PCL)) and the other layer allowing for short-term tissue ingrowth 
and drug delivery (i.e., poly(lactic-co-glycolic) acid (PLGA)).  In vitro degradation 
and several in vivo studies were completed to evaluate the scaffold performance and 
refine the design.  Incorporating 3-D printed polymeric rings into the fibrous scaffold 
enhanced mechanical performance and growth factors and cells improved cellular 
response and tissue ingrowth.  Additionally, research techniques were refined to 
analyze outcomes of these experiments, including microCT and stenosis 
quantification.  The application of electrospun materials to tracheal defect repair was 
taken from idea to preclinical practice in this thesis and has established a platform for 
further research and development, with the potential for translation to clinical use. 
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CHAPTER 1:  Introduction 
 
My dissertation encompasses the characterization of electrospun scaffolds for 
tracheal tissue engineering.  Tracheal stenosis or obstruction can occur in the 
pediatric and adult population, with occurrences due to congenital or acquired 
development.  Although this disease is rare, it is highly fatal.  Current treatment of 
small defects is laryngotracheal reconstruction (LTR), where autologous rib cartilage 
is used to augment the airway and increase the circumference.  Treatment for long-
segment defects is slide tracheoplasty which involves removing the stenosed segment 
and joining the two ends of the trachea in a specialized way.  These treatments are 
limited by donor tissue availability, surgical procedure difficulty, and added 
complications for patients.  A tissue engineered scaffold that is not reliant on donor 
tissue or complicated surgeries is needed.  I used an electrospun scaffold with 
gradient layers of poly(lactic-co-glycolic) acid (PLGA) and polycaprolactone (PCL).  
Reinforcing rings were added to assist with mechanical support.  Growth factors and 
cells were incorporated into these scaffolds to determine their effect on cartilage-
formation.  The aims of this research were to, 1) synthesize and characterize 
mechanically reinforced scaffolds with radial gradients of materials and encapsulated 
growth factors and 2) to evaluate the tissue engineered tracheal constructs in vivo.   
The first aim was to develop the electrospinning technology for the research 
group and to establish the parameters required to obtain the tracheal scaffolds.  Once 
the scaffold technology was developed, the scaffolds were characterized to determine 
how the organization of the polymer gradient and how in vitro aging affected mass 
 
2 
loss, molecular weight, porosity, fiber morphology, and mechanical properties.  The 
second aim was to determine the functionality of the scaffolds in an in vivo model.  
Several pilot studies and one full-scale study were performed.  The thesis chapters 
follow the progression of the aims.   
Chapter 2 is a thorough literature review of the status of tracheal tissue 
engineering research.  The chapter elucidates all of the approaches used to create a 
tissue engineered trachea, including biomaterials/scaffolds, cells, and culture 
conditions.  A clinical perspective was imparted in the review to bridge the bench top 
research and clinical need, in part with the assistance of collaborator and committee 
member, Dr. Robert Weatherly.  The knowledge and perspective gained from writing 
Chapter 2 inspired the pursuit of electrospun scaffolds for tracheal applications, as 
little research had been done in this space.   
While the in vivo pilot studies were conducted first to establish functionality 
of the scaffolds, Chapter 3 provides the basis for in vitro characterization of the 
fibrous scaffolds.  Several different scaffold designs were subjected to simulated 
physiological conditions and characterized through the 12 week degradation.  
Scaffold morphology, fiber diameters, porosity, mass loss, molecular weight, and 
mechanical properties (i.e., tensile, tube flattening, suture retention, and burst 
pressure) were tested. 
Chapter 4 and 5 address the second aim to characterize the scaffolds in an in 
vivo model.  Chapter 4 is a compilation of all of the pilot studies, including 1) the first 
in vivo study by our research group with the trachea, which was an evaluation of a 
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monolayer, electrospun scaffold in a patch-type defect (n=2), 2) evaluation of 
polymer gradients and growth factor encapsulation in patch-type defects (3 groups 
with n=2), and 3) evaluation of mechanically reinforced tubular scaffolds in 
circumferential defects (2 groups with n=2).  With the positive results of the patch-
type defect studies (e.g., no fatalities), a full-scale in vivo study (n=5) with the 
gradient, mechanically reinforced scaffolds was performed (Chapter 5). 
Chapter 6 provides a summary of my thesis work and highlights any trends 
and observations from the research.  With the informed perspective obtained from 
conducting this research, I identify areas of improvement for this technology and 
future directions for this research. 
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CHAPTER 2:  Overview of tracheal tissue engineering: clinical need 
drives the laboratory approach
1
 
 
ABSTRACT 
Breathing is a natural function that most of us do not even think about, but for 
those who suffer from disease or damage of the trachea, the obstruction of breathing 
can mean severe restrictions to quality of life or may even be fatal.  Replacement and 
reconstruction of the trachea is one of the most difficult procedures in 
otolaryngology/head and neck surgery, and also one of the most vital.  Previous 
reviews have focused primarily on clinical perspectives or instead on engineering 
strategies.  However, the current review endeavors to bridge this gap by evaluating 
engineering approaches in a practical clinical context.  For example, although 
contemporary approaches often include in vitro bioreactor pre-culture, or sub-
cutaneous in vivo conditioning, the limitations they present in terms of regulatory 
approval, cost, additional surgery and/or risk of infection challenge engineers to 
develop the next generation of biodegradable/resorbable biomaterials that can be 
directly implanted in situ.  Essentially, the functionality of the replacement is the most 
important requirement.  It must be the right shape and size, achieve an airtight fit, 
resist restenosis and collapse as it is replaced by new tissue, and be non-
immunogenic.  As we look to the future, there will be no one-size-fits all solution.   
 
 
 
1
Published as Ott L.M., Weatherly R.A., and Detamore M.S., “Overview of tracheal tissue 
engineering: clinical need drives the laboratory approach,” Invited review for Annals of Biomedical 
Engineering, 39(8) 2091-2113, 2011. 
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INTRODUCTION 
Tracheal repair procedures date back to the late 19
th
 century, and yet no 
predictably effective treatment for tracheal stenosis has been established that easily 
returns normal function to the trachea.
115
  Although tracheal stenosis is a rare disease, 
the mortality rates for long-segment tracheal stenosis (abnormal narrowing) and 
atresia (abnormally closed or absent trachea) are nearly 77% and 100%, respectively, 
as summarized by Fuchs et al.
26
  Many issues such as neoplasms, tracheotomy, 
congenital disorders, prolonged endotracheal intubation, and other types of tracheal 
trauma affect the tracheal lumen and can cause stenosis or tracheomalacia.  As a 
result, any damage to the trachea can compromise speech, deglutition (swallowing), 
respiration, mucociliary clearance, and immune protection from inhaled or ingested 
antigens
39
—all important functions for survival.   
This review seeks to summarize tissue engineering’s role in tracheal defect 
repair with a specific focus on the biomaterials and culture conditions used to create a 
tissue engineered trachea.  While much research has developed in airway tissue 
engineering (vocal fold, lung, etc.), the purpose of this review is to give an in-depth 
view of tracheal tissue engineering.  Many excellent trachea tissue engineering 
reviews exist,
5, 7, 14, 22, 114
 but the focus is either clinical or experimental.  The purpose 
of this review is to combine both aspects, and to highlight studies with approaches 
that are clinically translatable. 
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SURGICAL STANDARDS 
Replacement or reconstruction of the trachea is one of the most difficult 
procedures in otolaryngology—head and neck surgery.
85
   An optimal treatment has 
not yet been found, but current treatments for tracheal disease involve surgical 
repair.
32
   The most common surgical procedures for severe stenosis are resection of 
the affected areas followed by end-to-end anastamosis
37
 (surgical joining of two 
trachea ends to allow air flow from one segment to the other), or cartilage 
augmentation of a focal region of stenosis.  For determining the appropriate surgical 
approach based on the affected area, a general algorithm can be applied as follows:  
(1) in short segment stenosis involving the larynx, augmentation is preferred 
over resection and re-anastamosis. 
(2) for short segments not involving the larynx, resection and re-anastamosis 
are preferred over augmentation, and  
(3) in long segment stenosis, a patch (augmentation), usually with fascia or 
pericardium, or slide tracheoplasty are typically used.   
Resection and primary anastamosis can create tension in the trachea, and are 
only recommended for defects less than half of the length of the adult trachea and one 
third of pediatric trachea.
34
  Long segment defects (greater than 50% of trachea 
length) make up approximately half of trachea stenosis cases.
26
  In many cases, 
therefore, replacement tissue is utilized to expand the size of the tracheal lumen.   
In 2002, Grillo
34
 summarized all tracheal replacement methods either in use or 
under investigation, and divided them into five categories: foreign materials, 
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nonviable tissues, autogenous tissues, tissue engineering, and tracheal transplantation.  
Kucera et al.
55
 and Doss et al.
22
 also provided a two part summary of tracheal 
reconstruction using replacement materials and tissues.  Each replacement possesses 
problems when implanted.  One example of a common replacement material, used in 
the laryngotracheal reconstruction (LTR), is costal cartilage.  Costal cartilage is the 
current “gold standard” material for LTR;
27
 however, harvesting costal cartilage can 
cause donor site morbidity, including pneumothorax, pneumonia, and changes in the 
thorax contour.
65, 81, 121
  Shape and length constraints are also drawbacks to the use of 
costal cartilage in some cases.  According to Grillo,
33
 tissue engineering techniques 
show promise for creating a usable tracheal graft.  
 
CLINICAL NEED 
Neville et al.
76
 outlined characteristics for ideal tracheal replacements that are 
also applicable to tissue engineered trachea constructs (Table 2.1).  In addition to that 
list, tissue engineering techniques will preferably produce a construct that is ready for 
immediate implantation (i.e., “off-the-shelf” accessibility).  To meet this goal, the 
construct must either have a short fabrication time or be capable of being preserved 
for future use (i.e., reasonable shelf-life).  Materials and cells for the tracheal 
construct should also be easily accessible (little to no donor site morbidity) and 
available (overcome the limited supply of transplantable tissue and organs).  Along 
with accessibility of materials, the construct should be easily implanted into the 
patient, without need for complex, invasive or multi-stage surgeries.  The construct 
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must also be easily vascularized for nutrient transport, have the ability to grow with 
the patient (especially in pediatric cases), have relatively low cost, and be 
noncarcinogenic.  Tissue engineering of the trachea using the appropriate scaffold, 
cells, and culture conditions could possibly meet all of these requirements, but all of 
these characteristics must still be optimized. 
The first tissue engineered trachea experiment was published in 1994 by 
Vacanti et al.,
124
 where polyglycolic acid (PGA) fibers seeded with chondrocytes 
were implanted into the cervical trachea of the rat.  Since then, a myriad of groups 
have designed tissue engineered tracheas using a wide variety of techniques.  To 
readily describe these studies, the remainder of this review is divided into three 
primary sections:  (1) Biomaterials, (2) Cells, and (3) Culture Conditions for Tissue 
Engineered Tracheas.   
 
BIOMATERIALS FOR TISSUE ENGINEERED TRACHEA 
In the history of trachea replacement, numerous materials have been utilized 
to repair segments of the trachea, ranging from stainless steel
122
 to collagen.  These 
materials typically have been bio-inert and not resorbable or biodegradable.  One 
historic example of these prosthetic materials is the Neville prosthesis, which was 
used clinically until dehiscence occurred at the interface between the prosthesis and 
host tissue.
122
  With the advent of tissue engineering, biodegradable and/or porous 
materials with the ability to support tissue in-growth became the focus.  There are 
four categories of such scaffolds that have been employed in trachea tissue 
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engineering to date: “scaffold-free”, naturally-derived materials, synthetic materials, 
and a combination of materials.     
 
“Scaffold-free” approaches 
Scaffold-free culture, in this context, involves any approach (e.g., cell sheet or 
aggregate technologies) that develops tissue-like constructs without the use of 
biomaterial scaffolding.    Scaffold free culture for trachea replacement has only been 
evaluated within the last 6 years.   
The primary advantage of this method is less inflammation since foreign 
biomaterials are not included in the construct.  This approach may, however, 
compromise mechanical integrity.  Most scaffold-free approaches rely on a temporary 
stent to maintain the shape of the trachea.  In one example using an LTR patch 
procedure, Gilpin et al.
29
 did not include a stent when they implanted their 
chondrocyte sheet in rabbits.  The construct exhibited no signs of inflammation, but 
the graft buckled and migrated into the laryngofissure.  In another study, Tani et al.
117
 
wrapped a chondrocyte sheet around a silicon tube and tested the construct in a 
rotating bioreactor.  While the construct maintained shape after the silicon tube was 
removed, the elastic intensity (measured with a rheometer) was only one-third of 
native trachea cartilage, while the GAG content was 72% of native trachea cartilage.  
Wu et al.
132
 created a chondrocyte macroaggregate, which was wrapped around a 
silicon tube and implanted subcutaneously in 8 rabbits for a period of 8 weeks.  
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Cartilage formation was evident, but the mechanical properties were significantly 
lower than native cartilage and epithelialization was not addressed.   
In an orthotopic application, Weidenbecher et al.
129
 developed bioreactor-
formed chondrocyte sheets that were layered with a strap muscle flap around a silicon 
tube, which were then inserted into a circumferential defect in a rabbit trachea for a 
period of up to 39 days after first being allowed to mature in a paratracheal position.  
While the construct was vascularized and cartilage-tissue was detected, fibrous tissue 
developed in the lumen, causing a fatal airway obstruction in all animals in the study.   
Although chondrocytes have been the main focus of scaffold-free trachea 
constructs, Zhang et al.
143
 used a bone-marrow derived chondro-induced cell sheet 
wrapped around a poly(lactic-co-glycolic acid) (PLGA) tube and cultured it in a 
spinner flask. 
After 8 weeks of culture, histology and GAG content analysis revealed 
cartilage-like tissue.  An epithelial cell based aggregate was formed on temperature 
responsive dishes, and then placed into the lumen of a Dacron support prosthesis.  
After heterotopic (subcutaneous) implantation for 4 weeks, followed by orthotropic 
implantation in rabbits, the epithelial cell sheets formed pseudostratified columnar 
epithelial cells on the lumen of the construct.
47
   
Overall, there have only been a few studies that have utilized the scaffold-free 
or cell sheet approach for tracheal tissue engineering.  Different techniques were used 
to create these cell-sheets/microaggregates, but they have not yet been fully studied 
and compared to determine whether these techniques are capable of producing a 
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construct ideal for trachea tissue engineering.  The main disadvantage of this 
approach is an apparent inability of the construct to maintain the shape of the trachea. 
 
Naturally-derived materials 
Naturally-derived materials have been applied to trachea tissue engineering; 
specifically, decellularized tissue, collagen, hyaluronic-acid, and silk fibroin.  
Decellularized tissue scaffolds have been used in multiple areas of tissue engineering, 
and Macchiarini et al. 
66
 proved that they could also be used in a clinical trachea 
tissue engineering paradigm.  Decellularized aortic grafts,
102
 jejunum,
67, 126, 127
 
bladder,
28
 and trachea
28, 30, 43, 66
 have been utilized for tracheal replacement.  These 
scaffolds have been used with or without cells; however, Go et al.
30
 observed 
contamination and infection in constructs not seeded with epithelial cells in their pig 
model after a period of 11 days.  Remlinger et al.
93
 observed scaffold degradation 
after they implanted hydrated xenogeneic decellularized trachea extracellular matrix 
in dog tracheas for 8 weeks.  For future studies, the authors suggest adding 
chondrocytes to the scaffolds, with the goal of replacing the degrading scaffold with 
cartilage.  Preservation methods of such scaffolds also seem to have an effect on 
regeneration.  Gilbert et al.
28
 did not observe any cartilage formation in their 
decellularized trachea and bladder constructs when implanted in dogs for 6 months, 
and they hypothesized this may possibly have been due to lyophilization and freeze-
drying of their construct before implantation.  Seguin et al.
102
 studied how 
cryopreserved, decellularized, and glutaraldehyde-treated aortic grafts behaved as 
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stents in the sheep trachea for a period of up to 12 months.   They observed that the 
cryopreserved grafts regenerated respiratory epithelium and cartilage better than the 
other two grafts.   
Other naturally-derived scaffolds include hyaluronan-based scaffolds, which 
have been shown to support chondrocyte growth in bioreactor culture.
37
  However, in 
vivo rabbit implantation of allogeneic chondrocyte-seeded hyaluronan-based scaffolds 
(12 weeks) caused a nonspecific foreign body response and eventual degradation of 
tissue engineered cartilage.
128
  As this reaction has not been observed in knee articular 
cartilage defects, the authors hypothesized that an unfavorable microenvironment 
may exist in the neck (i.e., vascularized environment with different immunological 
properties than the knee).
128
  Lastly, silk fibroin has also been proven to be 
biocompatible in rabbit tracheas for 12 weeks, with fibroblasts and capillary vessels 
integrating into the material.
77
   
 
Synthetic materials 
Synthetic scaffold materials have been used since the advent of tissue 
engineering.  The synthetic scaffold materials used individually (not in combination 
with other materials) in tracheal tissue engineering have included polyglycolic acid 
(PGA),
35, 51, 124
 polylactic acid/polyglycolic acid (PLA/PGA),
64
 poly(lactic-co-
glycolic acid) PLGA, polyester urethane,
139
 poly(ethylene oxide)-
terephthalate/poly(butylene terephthalate)(PEOT/PBT),
73, 113
 gelatin sponge,
40
 
polyethylene oxide/polypropylene oxide copolymer (Pluronic F-127), and 
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polytetrafluoroethylene (PTFE).
68
  Biocompatibility and immune response to 
synthetic materials are concerns.   
Vacanti et al.
124
 observed no immune response to PGA in nude mice; 
however, Kojima et al.
51
 observed poor cartilage formation in the same PGA 
constructs in an immunocompetent animal (sheep) for 7 days, which the authors 
concluded could have been due to an inflammatory response.  A similar immune 
response was observed in PLA/PGA constructs in rabbits.
64
  However, pre-culturing 
the PLA/PGA construct for two weeks before implantation allowed for ECM 
formation and cell in-growth.
64
  Luo et al.
64
 hypothesized that inflammatory acidic 
degradation products were cleared from the scaffold and cells had begun to fill the 
scaffold, thereby preventing blood cells from invading the construct and triggering an 
immune response.  Other synthetic materials, like Pluronic F-127, do not have acidic 
degradation products, and have been shown to support cell attachment and growth.  
For example, chondrocyte seeded Pluronic F-127 was pre-cultured subcutaneously in 
three pigs, and then moved to an anterior defect in the trachea.
46
  The pigs survived 
for 3 months, and excellent neocartilage formation and graft integration into cricoid 
area were observed.  
 
Combination of materials 
Finally, combinations of materials, both synthetic and natural, have been 
investigated for tracheal tissue engineering.  The majority of tissue engineered 
tracheas have been combinations of two or more materials, usually involving a coated 
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or layered construct.  Collagen-coated polypropylene mesh reinforced with a 
polypropylene mesh cylinder is a trachea prosthetic that has been extensively 
studied.
74, 75, 78, 82-86, 98, 103, 109, 111, 120, 137
  There have also been many alterations on the 
basic collagen/polypropylene scaffold, by adding a cell loaded collagen gel to the 
outer surface of the construct,
78, 109
 coating vitrigel on the epithelium,
111
 and coating 
poly (L-lactic acid-co-ε-caprolactone) on the lumen.
98
   
Coating scaffolds with peptides, like the RGD cell adhesion ligand, is another 
approach used to enhance cell attachment.  For example, chondrocyte-loaded, RGD-
modified alginate was coated on PGA mesh and implanted in rabbit trachea for up to 
20 weeks.
35
  Mature cartilage was formed in the constructs, however, the RGD did 
not have an effect on cartilage formation.  Another composite culture study compared 
coating a polyurethane sponge (PS) with collagen, fibronectin, RGD, or apatite.
138
  
Some inflammation occurring in the RGD constructs, and the apatite and fibronectin 
scaffolds appeared to perform better dog tracheas.  Although all constructs were 
inundated by sputum absorption.  
Other combination materials used a multi-layered approach.  For example, 
Komura et al.
53
 designed a 3-layer construct:  a collagen sheet on the luminal side to 
support epithelial ingrowth, a PGA nonwoven mesh inside, and an L-lactide/ε-
caprolactone coarse mesh on the outer surface for mechanical support.  In addition, 
basic fibroblast growth factor (bFGF)-loaded gelatin microspheres were added to the 
outer surface, which the authors used with the intent of enhancing chondrogenesis.
53
  
After the construct was implanted in rabbit tracheas for 3 months, some morbidity 
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occurred due to surgical issues, and in the surviving animals, it appeared that bFGF 
increased cartilage formation; however, the efficacy of the multi-layered design was 
not determined (i.e., no comparison to a control).  Another three layer construct was 
evaluated in circumferential defect repair, consisting of a silicon stent, collagen 
sponge, and gelatin sponge loaded with bone morphogenetic protein (BMP)-2.
136
  The 
silicon stent was removed at 8 weeks and the trachea maintained patency after 6 
months of observation.  However, this was only evaluated in one dog.   
  Aside from the composition of scaffold materials, the actual design of the 
scaffold has received some attention.  A majority of tracheal tissue engineering 
studies are focused on developing scaffolds for large circumferential defect repair, as 
these type of defects typically cannot be repaired with autografts or end-to-end 
anastomosis.  Less common are the “Y”-shaped defects for bifurcation repair.  Sekine 
et al.
103
  attempted to implant a “Y” shaped construct in dogs for up to 7 months.  
However, the survival rate was low due to air leaks.  In a long-term follow-up study, 
1 dog survived for 5 years with this construct.
75
   
In addition, a biomimetic approach in scaffold design and geometry has been 
considered by some groups.  For example, Moroni et al.
73
 explored how macroscopic 
topology (i.e., discrete cartilage arches) affected cellular metabolism and ECM 
production, and established that an anatomically designed scaffold (created from a CT 
image) created an environment for a high degree of chondrocyte differentiation in 
vitro as compared to cylindrical and toroidal tubular scaffolds.  The authors suggested 
that the imperfections in the anatomical construct created local niches for increased 
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cell-cell contact and thinner fibers for better chondrocyte attachment.
73
  The cause for 
increased cell performance in these anatomically shaped scaffolds requires further 
assessment, particularly in an in vivo model.  Other groups have focused on creating 
distinct ring shapes in the scaffold to mimic a native cartilage ring.  Kojima et al.
52
 
created a construct with a chondrocyte-PGA mesh inserted into helical grooves in a 
silicon tube, and the outer surface was coated with transforming growth factor (TGF)-
β2-loaded hydrogel microspheres.
52
  Cartilage formation was evident after 6 weeks of 
subcutaneous implantation in nude rats; however, the relationship between the 
geometry and mechanical properties was not evaluated.  Lin et al.,
61
 recreated the 
tracheal ring structure by inserting chondrocyte-seeded collagen in the grooves of a 
tubular PCL scaffold.  The relationship between construct design and performance 
was not the focus of this study, but the construct resisted collapse and neocartilage 
was formed when implanted into rabbit tracheas for 52 days.  In another trachea ring 
replacement approach, Igai et al.
40
 removed the trachea rings in dogs without 
disturbing the mucosa, and then filled the gaps with BMP-2-loaded gelatin.  
Histological analysis revealed cartilage and bone infiltration in the ring-shaped 
defects after 12 months.   
 
Summary 
Many different scaffold materials have been utilized for tracheal tissue 
engineering, each with their own inherent strengths and weakness.  By combining 
materials (or layering materials), the limitations of one material can be compensated 
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for by another material.  However, this added complexity may require more 
fabrication time, cost, regulatory approval time and cost, and/or advanced fabrication 
techniques to assemble the layers.  Scaffold design has not been extensively 
addressed, so the importance of mimicking the biological structure on a macroscopic 
level has yet to be proven.  In translating to clinical utility, the most straightforward 
approach that imparts requisite structure, function, and integration with host tissue 
until replaced by cellularized tissue may be the most successful. 
 
CELLS LINES USED IN THE TISSUE ENGINEERED TRACHEA 
Native trachea tissue is composed of hyaline cartilage, trachealis muscle, 
fibrous tissue, mucosal tissue, and a delicate vasculature.  Thus, some of the more 
common cell types found in the trachea include chondrocytes, smooth muscle cells, 
ciliated pseudostratified columnar epithelial cells, goblet cells, fibroblasts, and 
endothelial cells.  Tracheal tissue engineering has utilized a range of cell types, from 
chondrocytes to mesenchymal stem cells, obtained from many different donor tissues.  
The use of cells in a tissue engineered trachea can be divided into three strategies: 
acellular, single cell type, and multi-cell types.  In addition, more recent studies using 
stem cells will be highlighted in an additional subsection. 
 
Acellular constructs 
Acellular constructs rely on the biomaterial and any added growth factors to 
harness the body’s ability to allow cells to populate and integrate into the material.  In 
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these constructs, all cells must migrate into the material from the surrounding native 
tissue.  This strategy is often used for proof-of-concept materials that incorporate 
cells in later studies.  Examples of acellular constructs are decellularized tissue 
matrix
43
 and collagen coated polypropylene mesh.
82
   The influence of growth factors 
on tissue in-growth has also been evaluated acellularly, with some cartilage and bone 
formation observed in the implants in dog tracheas after harvest and examination .
40, 
136
 
 
Single cell type 
Bioengineered trachea research has primarily employed the one-cell-type 
strategy.  Many studies have utilized chondrocytes or epithelial cells to populate 
trachea constructs.  Chondrocytes were used in Vacanti’s first attempt at tracheal 
tissue engineering,
124
 and have been used extensively since then, in hopes of creating 
functional bioartificial cartilage.  Creating functional cartilage provides the needed 
support to prevent tracheal collapse.  Chondrocyte culture is a well established 
procedure, however, de-differentiation of chondrocytes during culture is a 
limitation.
125
  Often, creating a three-dimensional environment using coated culture 
dishes (agar
139
) or bioreactors, may help to preserve the chondrocyte phenotype.   
While native epithelial cells have been shown to migrate onto the lumen of 
tissue engineered constructs, re-epithelialization and mucosalization takes a 
considerable length of time.  For large segment reconstruction, mucosal growth over a 
construct is even slower, and represents a significant problem.  Without epithelium, 
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constructs can be susceptible to bacterial invasion, granulation tissue formation, and 
restenosis.
34
   
The source of chondrocytes and epithelial cells is a crucial consideration for 
researchers, as an immune response (autologous versus allogeneic source) or donor 
site morbidity would be highly undesirable.  Human tracheal chondrocytes may have 
the chondrogenic potential to form tissue-engineered cartilage for clinical use.
54
  
However, obtaining tracheal chondrocytes involves an invasive harvesting procedure 
from the tissue that is targeted for regeneration, so the clinical relevance of this 
approach may be limited.  After multiple side-by-side comparisons of chondrocyte 
sources (nasal, articular, auricular, tracheal, costal),
37, 49, 127
 the difference in donor 
site morbidity seems to be the main disparity.  The only quantitative difference 
between isolation locations was seen by Henderson et al.,
37
 where improved 
mechanical properties and ECM production were observed in auricular chondrocytes, 
but this was not confirmed by other studies.  While the best source for chondrocytes 
has not been agreed upon, avoiding the removal of trachea cells would be 
advantageous.  In general, the best method would involve easy retrieval of a relatively 
small number of donor cells that could be expanded in vitro or even directly seeded 
into the scaffold in the operating room, resulting in limited donor site morbidity.  
  
Multiple cell types 
The most complex approach for populating trachea constructs is to create a 
composite of cell types.  Prior to adding the cells to the scaffolding, researchers have 
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cultured the cells together or separately.  Sometimes, the co-culturing of cell types 
can be synergistic.  Chondrocytes and respiratory epithelial cells have been co-
cultivated for trachea replacement, and many different methods have been 
investigated.  One study evaluated the performance of (1) epithelial cells on 
chondrocyte pellets, (2) epithelial cells on native cartilage explants, and (3) co-culture 
on separate sides of collagen membranes.
89
  Immunohistochemical staining revealed 
expansion and differentiation in the epithelial layer of the third method.  The authors 
of this study concluded that the culture conditions of the third method (collagen 
membrane system); a basal lamina equivalent, fibroblast conditioned medium, and 
air-liquid interface; were required for epithelial cell proliferation and differentiation.
89
  
Another group cultured human respiratory epithelial cells and chondrocytes 
separately on 3D scaffolds, and then fused the two constructs together with fibrin 
surgical adhesive.  After 5 days in culture, the constructs remained viable and the 
layers were appropriately adhered to each other.
20
   
Chondrocyte and epithelial cell constructs have been seeded abluminally and 
luminally, respectively, to create a biomimetic construct.  These constructs have been 
introduced into subcutaneous pockets of nude mice.
50, 97
 At the conclusion of 6 
weeks, the ECM content of the tissue engineered cartilage was similar to native 
cartilage, and histology revealed mature cartilage and pseudostratified columnar 
epithelium.
50
  The function of these chondrocyte/epithelial cell constructs still needs 
to be evaluated in the in vivo trachea.  However, this biomimetic seeding strategy has 
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had repeated success in human, when seeding chondrocytes differentiated from MSCs 
on the exterior surface and epithelial cells on the interior surface.
66
 
Other combinations of cells utilized for trachea repair are epithelial cells and 
fibroblasts,
31
 endothelial cells and epithelial cells,
142
 chondrocytes and fibroblasts,
51
 
fibroblasts and muscle cells,
67
 and bone marrow stromal cell-derived chondrocytes 
and epithelial cells.
30, 66
  Walles et al.
126
 evaluated an even greater number of cell 
types; seeding chondrocytes, bone marrow-derived smooth muscle cells, bone 
marrow-derived endothelial cells, or respiratory epithelium on a decellularized 
matrix.  More research is needed to determine whether multiple cell types can be 
incorporated onto one construct at one time and whether this approach is clinically 
beneficial or practical (i.e., multiple biopsy sites).  This elaborate approach would 
need to be justified and the benefits must outweigh any additional costs.    
 
Stem cells    
The most ideal cell type is one that comes from a single source and can 
differentiate into the required cell types.  Adipose-derived stem cells,
109
 bone marrow 
stromal cells,
25, 52, 66, 74, 126, 143
 and amniocytes
56
 have been utilized for chondrogenesis 
in the tissue engineered trachea.  Cell sources for airway epithelium include 
respiratory tract endogenous cells and exogenous cells from other tissues in the body 
(embryonic, bone marrow, amniotic fluid, etc.)
96
  For example, fully differentiated 
airway epithelium has been generated from embryonic stem cells through an in vitro 
culture process.
15
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Summary 
Although three major approaches exist for populating a tissue engineered 
trachea (acellular, single-cell, or multi-cell composite), a single source of cells 
harvested with little to no donor site morbidity or immunogenicity, with lineage 
specific differentiation capabilities, would be the most promising and clinically 
relevant approach.  With increasing efforts in stem cell research, technologies like 
induced pluripotent stem cells may hold great potential for tracheal tissue 
engineering.  However, regulatory challenges may postpone their introduction into 
mainstream use, and the leading candidate cell source today may be the patient’s own 
bone marrow. 
 
CULTURE CONDITIONS FOR TISSUE ENGINEERED 
TRACHEAS 
 
 Once the materials and cells have been determined, a decision must be made 
regarding culture conditions, if any.  Culture techniques can be used to prepare the 
constructs for tracheal implantation or to simulate the in vivo conditions.  These 
techniques include using in vitro culture, in vivo implantation, or a combination of 
these steps.  When deciding on culture conditions, researchers have to determine 
whether to use growth factors, certain revascularization techniques, and the location 
and type of implantation.  Summaries of tracheal tissue engineering studies are 
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provided in Table 2.2 through Table 2.5, where Table 2.2 summarizes in vitro studies, 
Table 2.3 outlines orthotopic in vivo studies, Table 2.4 includes heterotopic 
(subcutaneous) in vivo studies, and Table 2.5summarizes in vivo studies that implant 
the construct heterotopically and orthotopically. 
 
Growth factors 
Various research groups have exposed their constructs to growth factors at 
some point in the duration of the study.  While growth factors are a common culture 
medium component in trachea tissue engineering studies, only a few studies have 
included growth factors in the scaffold materials.  One method by which growth 
factors have been placed into a scaffold is by encapsulation in gelatin microspheres 
52, 
53
 or in gelatin sponges
40, 53, 136
 and coated on the trachea construct.  Another approach 
has been to perfuse growth factors into the construct.
113, 116
  Vascular endothelial 
growth factor (VEGF) perfusion through a Degrapol scaffold resulted in increased 
tissue ingrowth and capillary formation in an ex ovo chorioallantoic membrane 
(CAM) model, as compared to a VEGF precoated scaffold.
116
 The growth factors 
utilized in these studies were used to enhance angiogenesis (VEGF)
116
 or to improve 
chondrogenesis with bFGF,
53
 TGF-β2,
52
  or BMP-2.
40, 136
 
 
In vitro culture and in vivo implantation 
Once cells are added to the scaffold, through static or dynamic seeding, the 
constructs can then be exposed to various in vitro and/or in vivo conditions before 
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implantation.  Bioreactor and static culture have been used independently or in 
conjunction with each other.  One group showed that bioreactor versus static culture 
did not have an effect on the GAG content and mechanical properties of scaffold-free 
chondrocyte constructs.
117
  While constructs have been extensively evaluated in static 
or dynamic in vitro culture, ultimately they must be placed in an in vivo model to 
determine functionality and performance in a living organism.  Animal models used 
for tracheal tissue engineering vary from nude mice to pigs, and as of yet a standard 
animal model for tracheal research has not been established.
118
   
Before implantation into an animal model, pre-culturing the constructs in vitro 
may be an important step.  For example, Luo et al.
64
 suggested that in vitro pre-
culture of constructs may reduce inflammation of biomaterial-based constructs and 
promote better ECM formation once implanted in vivo.  A chondrocyte seeded 
collagen-PCL tubular construct was exposed to a rotating wall bioreactor in vitro, 
followed by orthotopic implantation in rabbits.  Unfortunately, formation of 
granulation tissue caused stenosis in all animals.
64
  Tan et al.
113, 116
 suggested 
implanting an intra-scaffold perfusion bioreactor, which combines in vitro seeding 
and culture with in vivo implantation, in emergency patients who cannot wait for the 
time consuming construct preparation.  The authors proposed to implant the 
bioreactor system into a patient, supported by an extracorporeal portable system 
pump.  This in vivo bioreactor concept has been practiced in vitro, but in vivo testing 
remains for future research.   
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In a unique approach to tracheal tissue engineering, one group evaluated the 
feasibility of surgically repairing tracheal defects in fetal sheep while in utero.
25, 26, 56
  
In three different studies, allogeneic chondrocytes, bone marrow stromal cells, or 
amniocytes were seeded onto PGA mesh and implanted in fetal tracheal defects 
approximately 3 weeks before birth.  This approach was feasible with a majority of 
the lambs surviving and able to breathe at birth.  Fetal sheep have been shown to 
tolerate non-allograft materials,
60
 so regeneration and integration of the TE constructs 
may have a better chance when performed in utero.  This in utero technique is a way 
to address tracheal stenosis early, but the ability to detect tracheal stenosis in utero 
and the overall risk of such an operation still remain as obstacles to the clinical use of 
such an approach. 
While sequence of culture conditions can vary, the size and location of 
implantation for in vivo studies can also differ.  Some studies implanted the tissue 
engineered trachea subcutaneously.
49
  In these cases, survival rates were usually high 
and tissue in-growth was observed; however, the functionality of the construct cannot 
be analyzed with subcutaneous implantation.  A majority of the tracheal tissue 
engineering studies placed the construct in a patch or circumferential defect in the 
trachea (orthotopically).  Survival rate and performance of the constructs were 
typically good in patch (or window) defects, while lower survival rates and more 
complications occurred in circumferential defect repair.  Alternatively, some 
researchers implanted the construct subcutaneously to precondition the construct, and 
then transplanted the construct orthotopically.
46
  An intricate approach was recently 
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introduced, where tracheal constructs were cultured in a perfusion bioreactor in vitro, 
followed by paratracheal implantation, and finally implanted orthotopically.
129
  While 
this is an elegant and complex approach, stenosis was observed in all cases, and the 
authors suggested this may have been due to the lack of epithelial lining.   
 
Revascularization 
In a recent ground-breaking transplantation study, an allograft trachea was 
implanted in a patient’s forearm for 4 months to revascularize the trachea construct.
18
  
Then, the allograft trachea was placed into the recipient’s tracheal defect.  Not only 
was the trachea revascularized, the patient eventually did not require 
immunosuppressive therapy after 229 days.  This clinical study was only one method 
of providing for enhanced vascular ingrowth in vivo.  Similar pre-conditioning 
approaches have been used for tissue engineered tracheas in animal studies (Table 
2.4).   
Walles et al.
70, 100, 126
 addressed vascularity concerns by preserving the 
vascular pedicle in decellularized intestine grafts, and perfusing the pedicle with 
endothelial cells.  Surrounding the construct with vascularized tissue is another 
revascularization technique.  For example, a PLGA-gelatin/polypropylene prosthesis 
construct was attached to omentum (highly vascular tissue) and then implanted in a 
circumferential defect in the dog tracheas.
48
  Obtaining an omentum/scaffold 
construct was challenging due to complicated isolation techniques (success rate 53%), 
however, once the omentum/scaffold constructs were implanted into the trachea, they 
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maintained an adequate inner diameter and had stable surfaces after 1 month.  
Matloub and Yu
68
 performed an acellular study with a polytetrafluoroethylene 
(PTFE) scaffold lined with a fascial flap and skin grafts in 20 rats for 3 weeks.  The 
fascial flap promoted blood vessel formation across the PTFE scaffold.   
Tan et al.
112
 addressed oxygen diffusion by incorporating an oxygen carrier 
(Oxygent) in their in vitro culture medium, and found that it enhanced epithelial cell 
metabolism.  However, reduced GAG content and histology revealed that Oxygent 
may have interfered with cartilage formation.  The authors noted that further testing 
would need to be done to evaluate the long term effects of Oxygent on cartilage.   
 
Summary 
 In this final and most important step, constructs must be exposed to optimal 
culture conditions in order to maximize their performance in living organisms.  
Culture techniques for tracheal tissue engineering range from simple to very complex.  
In addition to common static or dynamic in vitro culture and subcutaneous or 
orthotopic in vivo implantation techniques, researchers have occasionally combined 
these techniques to advance tissue regeneration or overcome drawbacks of using one 
technique alone.  The benefit of combining the techniques into a more complex 
sequence may have advantages to construct survival, but further side-by-side 
comparisons of these new combination techniques are needed to determine the best 
culture conditions, in order to prepare the constructs for human implantation.  As 
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tracheal constructs enter the clinical setting, a simple, expedient, and user-friendly 
approach would be ideal.   
 
CLINICAL STUDIES OF TRACHEA REGENERATION 
Only two groups have implanted a tissue engineered trachea in humans.  A 
group in Japan created a polypropylene reinforced mesh coated with collagen and 
preclotted with autologous blood, which has been implanted in eight human cases 
with a 4 year follow-up.
83, 86
  In contrast, a European team of collaborators from 
Spain, Italy, and the UK developed a decellularized donor trachea seeded with 
autologous cells, which has been implanted in one human case with an 18 month 
follow-up.
6, 66
   
The Japanese group has since added cells to their constructs, including bone 
marrow aspirate, bone marrow-derived stem cells, and fibroblasts.
74, 78
  They have 
also coated the lumen of the polypropylene/collagen construct with poly (L-lactic-
acid-co-ε-caprolactone) to delay degradation of the underlying collagen layer, which 
is intended to allow time for the host’s epithelium to migrate onto the collagen 
layer.
98
  According to news reports
1, 2
 and the medical literature,
44
 the European group 
has since repeated the decellularized trachea transplantation in additional patients, 
including two cancer patients and a pediatric patient.  In the pediatric case, the 
transplanted segment was lengthy (7 cm), so a polydioxanone (PDS) stent was placed 
in the lumen and successfully removed after 2 months.
44
  The patient was reported to 
be healthy.
44
  In an attempt to reduce construct preparation time, the European group 
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incorporated cells and growth factors (erythropoietin, granulocyte colony stimulating 
factor, and beta-transforming growth factor) into the decellularized scaffold intra-
operatively.
44
  This in situ approach followed the bionic tissue engineering concept 
proposed by Bader,
6
 where a cocktail of growth factors was used to prompt cell 
growth and differentiation (i.e., boosting factors, recruitment factors, and 
commitment factors).   
 
Summary 
 Two approaches to the use of tissue engineered tracheas have reached the 
clinical arena, and have been successful in humans.  While there has been some 
success, researchers continue to improve upon their respective approaches to address 
issues like complex preparation time, revascularization, and matching scaffold 
degradation to tissue integration.  These techniques are still in the case-by-case 
investigational phase, so a full scale clinical trial will be needed to determine 
functionality in a larger population with a more diverse set of trachea defect types.    
     
DISCUSSION 
Great amounts of time and research have been invested into tracheal tissue 
engineering, and the constructs that have been developed show promise for a 
clinically-useful tissue engineered replacement.  However, many problems have 
arisen, such as how to maintain structural support of the tissue-engineered construct, 
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controlling the resorption processes,
14
 minimizing the rejection response,
14
 optimizing 
re-epithelialization, and promoting revascularization.   
Even the first clinically transplanted tissue engineered trachea,
66
 which has 
functioned successfully in patients thus far, was limited by a long-preparation time, 
revascularization, and reliance on donor tissue.
99, 106, 133
  Even though some 
limitations exist with decellularized tissue, it is a short term solution that is helping 
patients with devastating tracheal diseases.  The reliance on donor tissue, however, 
for the decellularized scaffolds is a major limitation, and a synthetic construct may be 
a better long-term goal of this technology.  This obstacle could be overcome by 
fabricating a scaffold that mimics the decellularized tissue.  For example, using 
fibrous based scaffolds created through techniques like electrospinning could 
simulate the nanometer scale of the extracellular matrix.
91
  By further understanding 
the microscopic properties of the decellularized tracheal tissue, researchers may be 
able to use a biomimetic hierarchical approach to reverse-engineer these structures.   
   Revascularization is another major concern and needs to be addressed, as it is 
a crucial step in the translation of the tissue engineered trachea from the lab to the 
clinical arena.  While the tissue engineered tracheas that have been implanted in 
humans seem to be successful, they were not vascularized prior to implantation.  
Some researchers are concerned that the body cannot successfully revascularize these 
implants when placed orthotopically, and as a result the constructs may undergo some 
degree of necrosis.
17
  Many methods have been employed to revascularize tissue 
engineered tracheas, ranging from special surgical procedures (i.e., heterotopic 
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implantation
18
), to growth factors (e.g., VEGF
116
), to endothelial cell perfusion into 
the decellularized vascular pedicle.
126
  There is no simple and straightforward answer 
to revascularization, and researchers are not yet in agreement with regard to whether a 
pre-vascularized construct is needed.
17
  At the very least some vascularization is 
needed in tracheal tissue engineering to maintain construct viability, and future tissue 
engineered tracheas must include a plan for vascularization.  
Growth potential is another important aspect of tracheal tissue engineering.  If 
an implanted construct is vascularized, integration into the native tissue should follow 
and cells will slowly replace the biomaterial.  With the construct fully integrated into 
the tissue, it should have the potential for growth with the patient.  This growth 
potential has been assessed in vascular grafts.
105
  Growth potential in tracheal tissue 
engineering has not been extensively studied.  With the recent implantation of a 
decellularized donor trachea-based construct in a pediatric patient,
44
 this phenomena 
has to be accounted for in humans.  
A large number of studies in this review have investigated a composite of 
materials and/or cells to address the existing problems of tissue engineered tracheas.  
Birchall and Macchiarini
10
 suggested that a successful trachea construct should not 
rely on only one tissue type, but instead be a composite tissue that incorporates the 
mucosa, connective tissue, cartilage, etc.  Whether this means multiple cells types are 
needed, or one cell type could function with the ability to ideally be guided into 
different lineages according to spatial location, remains to be determined.  Stem cells 
have this differentiation potential, and further use of stem cells in trachea tissue 
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engineering warrants further investigation.  Specifically, stem cells have the potential 
to overcome invasive harvesting procedures, and the pluripotent characteristics could 
reproduce the diverse population of cells found in the trachea.  Utilizing stem cells 
with a scaffold that releases growth factors in a gradient manner,
21
 could regionally 
cue the cells to differentiate into the required cartilage, epithelium, and other tissues 
that exist in the native trachea. 
Combining scaffold materials could also be useful, where a composite of 
materials would be more biomimetic, with one type of material providing mechanical 
integrity of the construct, and the other materials creating a degradable, 
biocompatible environment for cells.  Multitudes of materials have been used in the 
trachea, and new material fabrication techniques and materials need to be considered 
and applied to tracheal tissue engineering.  For example, bioprinting of tissue is a 
relatively new fabrication technique,
72
 which could be applied to tracheal patches.  
While the literature claims that there are no optimal replacements for large 
circumferential defects, tissue engineering studies are evaluating both partial and 
circumferential defects.  So the question is, what types of trachea replacements are 
really needed?  And if repair of both types of defects (partial and circumferential) 
may be based on each individual case, then can a tissue-engineered trachea be tailored 
for both applications?  This one-size-fits-all approach is attractive from a fabrication, 
mass production, cost, and ease of use perspective; however, a patient specific 
solution may be more clinically applicable.  The technology does exist to create 
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patient specific tracheal replacement scaffolds; as seen in the CT generated, 
anatomically designed tissue engineered trachea.
73
  
Lastly, the types of culture conditions also need further development.  A 
longer time in an in vitro bioreactor or the use of in vivo subcutaneous pre-
conditioning would allow for tissue formation prior to implantation; however, this 
requires time and money, introduces regulatory challenges, and introduces risk for 
bacterial contamination.  Bader and Macchiarini
6
 suggested eliminating any culturing 
of cells or constructs, and implanting the construct with a special mix of growth 
factors used to induce physiological regeneration.  Tan et al.
113, 116
 attempted to 
eliminate the in vitro seeding and culture step by implanting a bioreactor with the 
trachea construct directly into an animal.  The value of in vitro culture needs to be 
further elucidated in side-by-side comparisons of constructs implanted in vivo with 
and without the in vitro pre-culture step.    
As the optimal construct is developed experimentally, regulatory 
considerations must also be kept in mind.  According to the FDA, a product can either 
be submitted as a device or as a drug-related item for ultimate approval.  The 
constructs mentioned throughout this review include biomaterials, cells, and proteins 
(growth factors), and as a result they could fall into both categories as a combination 
product.  As the complexity of the product increases, more regulatory standards and 
test methods are needed to evaluate the safety and efficacy of such products.  Thus, it 
could become more difficult to achieve regulatory approval and investment funding 
for commercialization of these combination products.  As a result, researchers are 
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challenged to find a tracheal construct that has a straightforward design.  Currently, 
decellularized tissue is FDA approved for a few applications, for example 
decellularized heart valves are approved for valve replacement.  Approval of such 
products is promising for allograft and tissue engineering products.  
 As there is no preferred treatment for tracheal stenosis, there exists a clinical 
need for tracheal replacement options.  As the field of tissue engineering attempts to 
develop tracheal replacements, multiple types and combinations of cells, scaffold 
materials, and/or culture conditions have been used.  The constructs that have reached 
clinical application thus far involve a combination of materials or a combination of 
cells, with and without in vitro preculture.  Critical assessment of the progress of 
tracheal tissue engineering provided in this review will hopefully illuminate methods 
to address vascularization, mechanical stability, fabrication time, and 
reepithelialization.  As we strive to bring trachea regeneration to the clinic, the most 
direct route would be to employ an off-the-shelf biomaterial, classified by the FDA as 
a medical device, capable of supporting cell infiltration without the need for any pre-
seeding, pre-culture or bioreactors.  However, additional layers of complexity may be 
required, such as seeding the construct with the patient’s own stem cells in the 
operating room, or incorporating growth factors into the construct, which if necessary 
would justify the associated pursuit of a more lengthy and costly regulatory process.  
The community has yet to establish an agreed-upon animal model, which will be 
necessary for initial screening of candidate products and treatment strategies for the 
clinic.  Recognizing that there is unlikely to be a “one-size-fits-all” approach, it is 
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possible that simpler strategies for tracheal patches may provide a more 
straightforward route to the clinic, whereas more complex strategies (e.g., cell 
seeding, heterotopic implant preculture, growth factor release, etc.) may be justified 
in terms of additional time and cost if they are necessary for regeneration of large 
circumferential defects. 
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CHAPTER 3:  In vitro characterization of gradient electrospun 
scaffolds for tracheal defect repair 
 
ABSTRACT 
 Tracheal stenosis and obstruction is a fatal condition, and current treatments 
include augmentation of the airway with autologous tissue.  A tissue-engineered 
approach would not require a donor source, while providing an implant that meets 
surgeon’s and patient’s needs.  A fibrous, polymeric scaffold organized in gradient 
bilayers of polycaprolactone (PCL) and poly-lactic-co-glycolic acid (PLGA) with 3-D 
printed structural ring supports, inspired by the native trachea rings, could meet this 
need.  In vitro degradation of various scaffold designs over 12 weeks revealed that 
scaffolds with the bioprinted rings had superior properties in tensile and radial 
compression, with at least a 3-fold improvement and 8.5-fold improvement, 
respectively, relative to the other scaffold groups.  The ringed scaffolds produced 
tensile moduli, radial compressive forces, and burst pressures similar to or exceeding 
physiological forces or native tissue data.  Scaffolds with a thicker PCL component 
had better suture retention and tube flattening recovery properties, with the monolayer 
of PCL (PCL-only group) exhibiting 2.3-fold increase in suture retention strengths.  
Tracheal scaffolds with ring reinforcements have improved mechanical properties, 
while the fibrous component increased porosity and cell infiltration potential.  These 
scaffolds could be used to treat various trachea defects (patch or circumferential) or in 
other tissue engineering applications.   
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INTRODUCTION 
 Tracheal tissue engineering is of particular importance because of the high 
mortality rates due to tracheal stenosis or obstruction.  Electrospun scaffolds gained 
attention for their biomimetic fibrous microenvironment and relative ease of 
fabrication.  These materials have excellent potential for tracheal application, as they 
are easily shaped into tubular structures for circumferential applications or into sheets 
for segmental patch applications.  Degradable polymers were chosen for their lack of 
reliance on donor tissues and ability to be replaced and regenerated by host tissue.  
Our scaffolds are designed into a graded bilayer with one layer providing long-term 
structural support (i.e., polycaprolactone (PCL)) and the other layer allowing for 
short-term tissue ingrowth and drug delivery (i.e., poly(lactic-co-glycolic) acid 
(PLGA)).  A polymeric ring of PCL) was incorporated into the fibrous scaffold for 
added structural integrity.  In the current study, seven different permutations of the 
scaffold were tested, 1) PCL alone, 2) PLGA alone, 3) PCL/PLGA co-spun/blend, 4) 
PCL/PLGA co-spun/blend, 5) PCL/PLGA bilayer, 6) PCL/PLGA graded bilayer, and 
7) PCL/PLGA graded bilayer with incorporated rings.  We evaluated the porosity, 
fiber morphology, molecular weight, mass loss, and mechanical properties of our 
scaffolds under in vitro degradation conditions (Figure 3.1).  In vitro characterization 
is crucial for scaffold design and pre-clinical efficacy building.  The purpose of the 
current study is to characterize the tracheal scaffolds and determine the design that 
meets physiological requirements.  We hypothesized that the PLGA would affect 
porosity and mass loss/molecular weight properties, the PCL component would 
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provide consistent elastic properties, and the ring would dramatically improve 
mechanical properties. 
 
MATERIALS AND METHODS 
Material fabrication 
Using a custom designed electrospinning apparatus, 2 mm thick electrospun 
fiber hollow cylinders (in all groups except for ring containing scaffolds) were 
fabricated following a slightly modified protocol established in a previous publication 
for our group 
58
.  A 7 wt% polycaprolactone (PCL; inherent viscosity 1.0-1.3 dL/g, 
LACTEL, Birmingham, AL) solution in hexafluoro-2-propanol (HFIP; Oakwood 
Chemical; Columbia, SC) and a 14 wt% poly(D,L-lactide-co-glycolic acid) 
copolymer (PLGA; 50:50 lactic acid : glycolic acid, acid end group, inherent 
viscosity 0.35 dL/g, Evonik Industries, Birmingham, AL) solution in HFIP were 
mixed.  Safety precautions, personal protective equipment and a well ventilated 
working environment were used when handling toxic solvents.  The solutions were 
placed in 20 mL syringes and fitted into programmable syringe pumps (PhD Ultra, 
Harvard Apparatus, Holliston, MA) set to extrude the solution at 5 mL/hr.  As the 
solution was extruded through a charged 20 gauge needle (+12 kV; Glassman High 
Voltage, High Bridge, NJ), the charged polymer was drawn from the needle tip to a 
negatively charged (-6 kV) rotating cylindrical stainless steel mandrel (7 mm 
diameter).    
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 To create the monolayer groups (Figure 3.1), 40 mL of PCL solution and 40 
mL of PLGA solution were electrospun to create the PCL monolayer and PLGA 
monolayer groups, respectively.  The PCL/PLGA co-spun monolayer group was 
created by electrospinning separate solutions of 20 mL of PCL and 20 mL of PLGA 
at the same time from opposite sides of the mandrel, simultaneously, collecting both 
fiber types on the mandrel.  The PCL/PLGA blend monolayer group was created by 
mixing equal volumes (20 mL each) of 7 wt% PCL and 14 wt% PLGA solutions prior 
to electrospinning (creating a 3.5 wt% PCL and 7 wt% PLGA solution for a total 
polymer solution of 10.5 wt%). 
 To create the bilayer group, 20 mL of PCL solution was electrospun onto the 
mandrel followed by 20 mL of PLGA solution.   
To create the gradient interface group, 12 mL of PCL was deposited, followed 
by co-spinning 8 mL of PCL and 8 mL of PLGA from two different needles on 
opposite sides of the mandrel to create the interface layer, followed by 12 mL of 
PLGA. 
To create the 3-D printed rings, a 3D CAD image was used to print 7 mm ID, 
11 mm OD, 2 mm thick PCL (MP05188, MakerBot filament, Brooklyn, NY) rings 
with a circular cross section(RepRapPro printer, Briston, UK). 
To create the gradient interface group with circumferential rings, 6 mL of 
PCL was deposited, the PCL rings were cut open on one end and wrapped around the 
cylindrical stainless steel mandrel at 3-4 mm intervals, 6 mL of PCL was deposited 
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over the rings, followed by co-spinning 8 mL of PCL and 8 mL of PLGA to create the 
interface layer, followed by 12 mL of PLGA. 
To prevent delamination of the layers, in between the deposition of layers, 
HFIP was lightly misted with an atomizer onto the outer surface of the scaffold to 
prepare the surface for the next layer.  Once the 2 mm wall thickness was achieved, 
the electrospun tube was removed from the collecting rod, lyophilized for 24 hours, 
sterilized using ethylene oxide, and aired in a fume hood for 24 hours.        
Degradation conditions   
Following ASTM F1635-11, the scaffolds were degraded in simulated 
physiological conditions.  Scaffolds were immersed in phosphate-buffered saline 
(PBS; P5386, Sigma, St. Louis, MO) at 7.4 ± 0.2 at 37°C.  To maintain stable aging 
conditions, the PBS-to-scaffold volume ratio was 100:1.  The pH was measured 
periodically and if an excursion beyond the specified pH range occurred the PBS was 
removed and refreshed with new PBS for all samples.  Samples were collected and 
washed at specific time points (0, 1, 2, 3, 4, 6, or 12 weeks) for analysis.    
SEM 
The scaffolds used for imaging represented all seven groups at the 0, 6, and 12 
week time points (n=3). All scaffolds were lyophilized overnight before being cut 
with a scalpel and placed on a specimen holder. The samples were sputter coated 
(Q150T ES, Quorum Technologies, East Sussex, England) with 30 nm of gold before 
being positioned in the SEM (Leo 1550 field emission, Carl Zeiss, Oberkochen, 
Germany).  
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They were subsequently placed under high vacuum at an accelerating voltage 
of 10 kV and working distance between 11.5-12.5 mm using the SE2 detector. Each 
sample was imaged at 500x, 1500x, 2500x, and 5000x magnification with a line 
integration time of 45 seconds. 
Porosity 
The scaffolds used for porosity calculation represented all seven groups at the 
0, 6, and 12 week time points (n=3). Porosity calculation was determined using the 
gravimetric method.  The mass of the sample was measured (scale ± 0.0001 g), 
followed by the inside diameter, outside diameter, and height (calipers ± 0.01 mm). 
Using this information, the apparent density and porosity were calculated according 
to the equation: ρapp= 4m/ πd
2
h, Porosity (%) = (1-ρapp/ρ) x 100, with m, d, h, and ρ as 
the mass, diameter, height, and bulk density, respectively. The bulk density (ρ) of 
PCL and PLGA were 1.081 ± 0.003 gm/cc and 1.324 ± 0.004 gm/cc, respectively.   
Mass loss 
The scaffolds used for mass loss represented all seven groups at the 0, 1, 2, 3, 
4, 6, and 12 weeks (n=3).  The mass loss was determined from the initial mass before 
degradation and the residual mass after rinsing with distilled water and lyophilizing.  
The results were reported as a percent mass loss versus degradation time.   
Size exclusion chromatography  
The scaffolds used for molecular weight analysis represented all seven groups 
at the 0, 1, 2, 3, 4, 6, and 12 weeks (n=3).  The residual mass of each scaffold were 
rinsed with distilled water, lyophilized, completely dissolved in chloroform (at 5 
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mg/mL), and filtered with a 0.02 µm filter (6809-2002; Whatman; Buckinghamshire, 
UK).  An HPLC system (CBM-20A, LC-20AB, SIL-10AF, CTO-20AC; Shimadzu; 
Kyoto, Japan) equipped with a column (PL1110-1520, PL1110-6504 (rated for 200-
400,000 g/mol); polystyrene/divinylbenzene matrix packing, Agilent Technologies; 
Santa Clara, CA) and multi-angle light scattering (MALS) (miniDAWN TREOS; 
Wyatt Technology; Santa Barbara, CA) and refractive index (RI) (RID-10A; 
Shimadzu; Kyoto, Japan) detectors was used. Samples were eluted at 1 mL/min and 
the column was maintained at 35° C.  A series (530, 3350, 30,000, 105,000, and 
245,000 Da) of narrow polydispersity polystyrene standards (TDS-PS-NB; Malvern; 
Malvern, Worcestershire, UK; 41930, 41925; Alfa Aesar; Ward Hill, MA; PL2012-
2001; Agilent Technologies; Santa Clara, CA) were used for calibration.  
After data collection, the RI and MALS data were analyzed for weight 
average molecular weight (Mw) values.  MALS data was analyzed with light 
scattering equations and Zimm plots using ASTRA 5 software (Wyatt) 
134
.  The dn/dc 
values for PCL and PLGA were empirically determined using the RI detector (RID-
10A; Shimadzu; Kyoto, Japan) (PCL = 0.0386 ± 0.0047 mL/g, PLGA = 0.0243 ± 
0.0025 mL/g).  RI data were analyzed with the polystyrene calibration curve using 
LC Solutions software (Shimadzu).  Mark-Houwink-Sakurada correction was not 
performed because the a and K constants for PCL and PLGA were not available in 
the literature 
11
.   
Tensile testing 
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The scaffolds used for tensile testing represented all seven groups at the 0, 3, 
6, and 12 weeks (n=3).  The testing method is similar to a previously published study 
from our group 
107
.  Briefly, tensile tests were performed using a uniaxial testing 
apparatus (Instron Model 5848, Canton, MA) with a custom-made stainless steel bath 
and grip assembly.  The grip faces were covered with 220-grit waterproof sandpaper 
that provided extra traction without damaging the specimens.   
Before testing, each specimen was thawed and equilibrated in 0.01M PBS at 
37 ± 1° C for 1 hour.  Prior to degradation, the specimens were cut into long 
rectangular strips from the tubular scaffolds, in a circumferential direction.  Prior to 
testing, the specimens were cut into 2 mm width strips using parallel razor blades.  
The average specimen thickness of 1.26 ± 0.39 mm and average width of 1.96 ± 0.16 
mm. Specimen dimensions were measured using calipers (± 0.01 mm).  After 
specimens were secured between the grips, a tare load of 0.03 N was applied to 
remove the laxity of the specimen.  The bath was then filled with PBS at 37° C and 
the specimen was allowed to re-equilibrate under this tare load for 10 min.  The 
average initial specimen length was 7.6 ± 1.0 mm. Preliminary studies determined 
that preconditioning is not required to obtain repeatable stress-strain curves and that a 
stress relaxation phase of 30 min was sufficient for the samples to reach equilibrium.  
Preliminary testing showed that 15% strain was safely below the onset of failure or 
slippage from grips (as indicated by sudden drops in force during step strain).   
A buoyant force correction was performed as described by Detamore and 
Athanasiou 
19
.  Briefly, the load exerted by the PBS on the top grip (Fb) was 
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measured empirically as a function of grip-to-grip separation (d). The measured force 
(Fm) was adjusted to the actual force experienced by the sample (F) by subtracting the 
effect of buoyancy, i.e., F(d) = Fm(d) - [Fb(d) - Fb(L0)], where L0 is the initial 
specimen length.  For a consistent buoyant profile, the bath height was held constant 
throughout all experiments and the bath was covered with parafilm to reduce 
evaporation.  The change in bath height was observed to be negligible at the end of 
each test. 
The testing protocol involved two phases:  1) applying a tensile load of 1% 
strain/sec to a 15% strain endpoint and 2) holding for 30 minutes at 15% strain.  
Stress-strain curves were generated from the continuous pull during the step strain to 
15%.  Young’s moduli were obtained from the linear regions of the stress-strain 
curves (no toe region observed).  Equilibrium moduli were obtained by dividing the 
average stress during the last 30 seconds of the relaxation phase by the step strain 
(15%).   
Burst pressure   
The scaffolds used for burst pressure testing represented all seven groups at 0, 
3, 6, and 12 weeks (n=3).  In accordance with ISO 7198:1998(E) and a previously 
published method 
23
, a 60 mL syringe (Becton-Dickenson, USA) was filled with 
water and placed in a syringe pump (KD Scientific, USA) set to run at a constant rate 
of 20 mL/min.  The syringe was attached to a length of surgical tubing, which was 
attached to a custom pressure sensor.  This pressure sensor was attached to another 
length of surgical tubing, which in turn was connected to a pediatric Foley catheter 
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(Coloplast, Denmark).  The catheter’s balloon was placed in the view field of a High 
Accuracy CCD Micrometer (Keyence, USA).  Pressure and scaffold diameter 
readings were measured and recorded at time intervals of 0.25 seconds as the tests 
took place using Labview 2010 software.   
Before the first test, the second length of surgical tubing was disconnected 
from the catheter.  To ensure no air was present inside the testing apparatus, water 
from the syringe was pumped through the apparatus and allowed to exit from the 
open end of the second length of surgical tubing into a separate container.  A separate 
syringe was used to repeatedly fill the Foley catheter with water and draw a vacuum 
until nothing but water was left inside.  At this time the catheter was also inspected to 
make sure the balloon filled evenly. The catheter and second length of surgical tubing 
were then reconnected prior to testing. 
Frozen scaffolds were allowed to thaw before they were removed from their 
sterile containers.  Scaffolds were submerged in a 37
° 
C warm water bath for 3 
minutes.  They were then removed from the water bath and placed over the balloon of 
the pediatric Foley catheter.  
The Labview 2010 recording program was initiated, and the syringe pump 
was run.  The pressure and width of the scaffold were monitored and recorded.  The 
syringe pump was deactivated and testing ceased when the scaffold failed or the 
pressure reached 30 psig.  The maximum pressure of 30 psig was chosen based on the 
physical constraints of the catheter, tubing connections, and syringe pump.   
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Using Microsoft Excel, pressure and change in diameter were plotted by 
group and by week.  The average change in diameter at 30 psig or failure for each 
group was calculated by week and recorded in a table.   
Suture retention   
The scaffolds used for suture retention testing represented all seven groups at 
0, 3, 6, and 12 weeks (n=3).  Suture retention tests were performed using a uniaxial 
testing apparatus (Instron Model 3342, Canton, MA) with a custom-made suture 
fixture (a hook attached to the top fixture).  Before testing, each specimen was thawed 
and equilibrated in 0.01M PBS at 37° C for 15 min.  The specimen geometry was 
elliptical with a 2.5 cm length and 1 cm width.  The elliptical shaped specimens were 
cut in half using a scalpel, so that the specimens were 1.25 cm length and 1 cm width.  
Specimens were oriented in the bottom grip in such a way that testing was done in 
two directions to simulate the suture forces in the radial and axial direction.  
Specimen dimensions were measured using a caliper (± 0.01 mm).  The average 
specimen thickness was 1.67 ± 0.71 mm.  A 4-0 PDS suture (M315A; Patterson 
Veterinary; Devens, MA) was placed 3 mm from the edge of the scaffold, tied into a 
loop and knotted 7 times.  The suture loop was attached to the suture holder and 
testing commenced.  The testing protocol involved pulling the suture loop at 1% 
strain/second (with the strain based on the length between bottom grip and the suture 
hole) until the sutured pulled through the scaffold (no tare load applied as the only 
measurement obtained was the final force).  The testing was not done under hydrated 
conditions as the scaffold was pre-hydrated and testing time was short enough to 
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ensure specimen remained hydrated during testing.  The force required to pull the 
suture through the scaffold was classified as the suture holding capacity (SHC) and 
the SHC divided by the scaffold thickness multiplied by the suture thickness was 
classified as the suture retention strength (SRS) 
80
.  
Tube flattening 
The scaffolds used for tube flattening testing represented all seven groups at 0, 
3, 6, and 12 weeks (n=3).  Unconfined compression testing was performed using a 
uniaxial testing apparatus (Instron Model 5848, Canton, MA) with a custom-made 
stainless steel bath and compressive platen assembly.  Before testing, each specimen 
was thawed and equilibrated in 0.01M PBS at 37° C for 1 hour.  Specimen 
dimensions were measured using a caliper (± 0.01 mm).  The specimen geometry was 
tubular with a 21.0 ± 1.7 mm length and an average inner diameter of 6.5 ± 1.3 mm 
and average outer diameter of 9.6 ± 1.6 mm.  The specimens were placed on the 
bottom platen and a tare load of 0.1 N was applied. The bath was filled with PBS at 
37° C and the specimen was allowed to re-equilibrate under this tare load for 10 min.  
Then the specimen was compressed in the radial direction at 0.1667% strain/second 
until reaching 80% strain (based on outer diameter) or until the load reached 45 N.  
The buoyant force was empirically determined to be negligible, a result of the top 
platen having a smaller volume and shorter distance traveled as compared to the 
tensile testing grips, resulting in a smaller buoyant force change as the fixture traveled 
through the PBS.  To account for specimen recovery, the sample outer radiuses were 
measured 1 hour after testing.   
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The tube flattening force at 100% strain (for inner diameter) was determined 
by examining the load-extension profile, where the scaffold compression region was 
linear and deviated from linearity at the point of flattening (100% strain based on 
inner diameter).  After the point of flattening, the load-extension profile exponentially 
increased as force from the bottom platen overtook the measured load.  To isolate the 
point of flattening, a linear regression of the compression region was established and 
the point of flattening was established to be at 15% deviation.  15% deviation 
represented a reasonable value to allow a reproducible value and objective basis for 
identification of flattening.  As a check, the extension at this point was compared to 
the caliper measured inner diameter to ensure a reasonable value had been identified.  
The actual caliper measurement was not used because the 100% strain could not be 
accurately determined by caliper measurements, due to difference in caliper and 
extension measurements after tare load.  Percent recovery was determined by taking a 
ratio of the pre- and post-test outer diameter based on caliper measurement. 
Statistical analysis  
Using one-way ANOVA and Tukey’s post-hoc analysis for SEM fiber 
diameter, porosity, Young’s modulus, equilibrium modulus, burst pressure diameter 
change, suture retention strength, tube flattening force, and tube recovery differences 
were determined to be significant if p<0.05.      
 
RESULTS 
Gross morphology 
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Gross morphological images of scaffolds were collected through the course of 
degradation (0, 1, 2, 3, 4, 6, and 12 weeks) (Figure 3.3).  The PCL component of the 
scaffolds was preserved through the course of 12 weeks, while the PLGA layer 
degraded (to a point that it could not be extracted from a tube) between 2 and 3 weeks 
(PLGA-only).  The PLGA component in the combination groups (Co-spun through 
Gradient+Rings) were preserved longer with the support of the intertwined or 
underlying PCL, as evident by a translucent layer at week 3 through 6 in Bilayer and 
7 images.  Sample degradation for other analyses followed a similar trend, where the 
PLGA-only scaffolds were completed degraded by 3 weeks.  
Fiber morphology 
The average fiber diameter of the scaffolds ranged from 1.5-6.3 µm across 
groups (Table 3.1). There was a distinct difference between the PCL and PLGA fiber 
appearance and diameters. The PCL fibers (PCL-only and Bilayer) had 75% smaller 
diameter fibers than the PLGA fibers (PLGA-only) at week 0 (p<0.05).  In addition, 
the PLGA fibers had a smoother, flatter surface with junctions between fibers 
deformed and fused together, while the PCL fibers were distinctly separate (Figure 
3.3).   
As the scaffold degraded, the PLGA component completely degraded after 
week 0 (in PLGA-only and Bilayer), lost its fibrous appearance and become an 
amorphous mass (Gradient), or retained its fibrous appearance up to Week 12 
(Gradient+Rings).  In the cases of blending or combining fiber types (Co-spun and 
Blended), the fiber morphology was unique.  Co-spun fiber morphology became more 
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irregular and distorted as the sample degraded (week 6) and regained a normal fibrous 
morphology at the final time point (week 12).  Blend fibers had a unique morphology 
upon degradation, where the length of a single fiber transitioned between one large 
diameter fiber to a bundle of smaller fibers (week 6 and 12). 
The sample cross-sections at week 0 revealed a fibrous cross-section in all 
groups, except for PLGA-only, which appeared to be more of a porous polymer mass.  
The layered scaffolds had a noticeable demarcation, indicating a transition between 
polymer types (Bilayer, Gradient, and Gradient+Rings).     
Polymer degradation 
The mass loss data analysis shows the change in mass over degradation time 
(Figure 3.4).  All groups experienced significant mass loss except for PCL-only, 
which is expected due to the slow degradation of PCL.  For the Co-spun, Blended, 
Bilayer, Gradient, and Gradient+Rings groups, the mass loss dropped off significantly 
after 3 weeks, which was attributed to the degradation of the PLGA component.  The 
blended and mixed scaffolds (Co-spun and Blended) experienced similar mass loss.  
Gradient scaffolds had the largest mass loss, while Gradient+Rings, a similar group 
with the exception of a PCL ring, had a much lower mass loss.  This is expected since 
the PCL component was preserved over 12 weeks and comprised a larger part of the 
mass of the Gradient+Rings samples.  No statistically significant differences were 
derived from these data. 
The PCL component of the scaffolds in all groups maintained a similar 
molecular weight over the 12 week degradation (Figure 3.5).  The pure PCL scaffold 
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(PCL-only) group had a consistent profile, maintaining a molecular weight around 
117 kDa (MALS) or 146 kDa (RI).  In contrast, the other treatment groups had 
molecular weight profiles that varied slightly more over time with a reduction in 
molecular weight at week 0 in the RI data, which could be due to PLGA and PCL 
chromatogram overlap thus reducing the Mw at week 0.. The Co-spun group degraded 
to a larger extent than any of the other groups. 
  The PLGA profile revealed that the molecular weight significantly decreased 
over 12 weeks (Figure 3.5).  The pure PLGA scaffolds (PLGA-only) exhibited a rapid 
decrease from 64 kDa at 0 weeks to 6.5 kDa at 2 weeks (MALS) or 65.9 kDa at 0 
weeks to 4.3 kDa at 2 weeks (RI).  While processing the PLGA SEC data, it was 
difficult to distinguish between the PLGA and PCL at 0 weeks, so no data were 
collected for combination scaffolds at week 0.  In the MALS profile, measurable 
PLGA was retained for 6 weeks in the blend Blend group, for 4 weeks in Bilayer, 
Gradient, and Gradient+Rings groups, and for 3 weeks in the Co-spun group.  In the 
RI profile, measurable PLGA was retained for 6 weeks in all Co-spun, Blend, and 
Gradient groups, for 4 weeks in the Bilayer group, and only 2 and 4 week data points 
for the Gradient+Rings group.   
Porosity 
Calculated porosity values revealed that the percent porosity significantly 
increased by 17-31% from 0 to 6 weeks for all groups (p<0.05), except for PCL-only 
and Gradient+Rings (Figure 3.6).  The porosity remained in the same range from 6 to 
12 weeks for all groups (no week 6 or 12 data for PLGA-only).   
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At 0 weeks, all groups had porosities in the range of 55-70% except for the 
PLGA-only group.  PLGA-only had the lowest porosity of all other groups at the 
week 0 (p<0.05).  The Gradient scaffolds had a higher porosity at week 12, as 
compared to the PCL-only group at week 12 (p<0.05). 
Mechanical properties   
Tensile Testing:  Stress-strain curves were linear through the tensile pull to 15% 
strain.  The Young’s modulus data showed that Gradient+Rings scaffolds 
outperformed by 5- to 250-fold increase moduli over all other scaffolds at the 
corresponding time points (p<0.05), except for PCL-only and Bilayer samples at 
week 0 (p<0.05) (Figure 3.7).  Equilibrium modulus was used to evaluation 
viscoelasticity of the scaffolds, by determining how much the scaffolds relaxed 
during a hold at constant strain.  The equilibrium modulus data followed trends 
similar to the Young’s modulus data where the Gradient+Rings samples 
outperformed all of the other groups (3-fold improvement over the PCL-only and 
Bilayer group) (p<0.05) (Figure 3.7).  Within the groups, the Young’s moduli and 
equilibrium moduli did not significantly change over time.    
Burst Pressure:  None of the scaffolds failed during testing (max-out pressure of 30 
psig) except for the Blend group at week 12.  The Blend, week 12 scaffolds average 
burst pressure was approximately 19.7 psig.  The change in scaffold diameter was 
measured from beginning of testing to the end of testing and a trend was observed 
across all groups in which the average change in diameter increased with degradation 
time (Figure 3.8).  No statistically significant differences were established. 
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Suture Retention:  Suture pull-out testing results had an overall general trend of 
decreasing suture holding capacity (SHC) (data not presented) and suture retention 
strength (SRS) over degradation time (Figure 3.9).  The direction of testing 
(circumferential and axial) did not affect SHC or SRS.     
 SRS data for circumferential direction revealed that within groups, Blend SRS 
decreased by 97% from 0 to week 3, 96% to week 6, and 99% to week 12 (p<0.05).  
Gradient SRS also had degradation dependent decline in SRS (~66%) from week 0 to 
week 3 (p<0.05).  Between groups, PCL-only, week 12 SRS were 2-fold or 400-fold 
higher than Co-spun and Blend scaffolds at week 12, respectively (p<0.05).  PLGA-
only SRS at week 0 were lower than all groups at week 0 (p<0.05).  Blend, week 3 
SRS were lower than PCL-only, Bilayer, and Gradient+Rings at week 3 (p<0.05).  
Blend, week 6 SRS were lower than PCL-only, Bilayer, Gradient, and 
Gradient+Rings at week 6 (p<0.05).  Gradient+Rings, week 12 SRS were higher than 
Co-spun at week 12 (p<0.05).       
Analysis of the SRS data in the axial direction revealed that within groups, 
Blend and Gradient scaffolds were affected by degradation with the SRS decreasing 
over time (Blend, week 0-week 6 and week 0- week 12; Gradient, week 0-week 3) 
(p<0.05).  Among groups, PCL-only and Gradient+Rings, week 12 had greater SRS 
than Co-spun and Blend at week 12 (p<0.05).  PLGA-only, week 0 SRS were lower 
than Blend, Bilayer, and Gradient at week 0 (p<0.05). 
 Tube Flattening:  The load required to flatten the scaffolds followed an 
overwhelming trend, where Gradient+Rings scaffolds outperformed all other groups 
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at corresponding time points (denoted by #, p<0.05) (Figure 3.10).  Degradation had 
no significant impact on tube flattening force within the groups. 
 The recovery of scaffolds after flattening revealed that Co-spun and Blend 
scaffolds at 3, 6, and 12 weeks remained in a flatter state (or recovered less) than 
PCL-only, Bilayer, Gradient, and Gradient+Rings at the corresponding time points 
(p<0.05).  Gradient+Rings scaffolds at week 0 recovered better than Co-spun and 
Blend at week 0 (p<0.05).  The blending or co-spinning of polymers resulted in 
tubular scaffolds that deform more permanently than other groups. 
Within the groups, PCL-only, week 0 scaffolds recovered less than at week 6 
(p<0.05).  Co-spun, week 0 scaffolds recovered better than week 6 (p<0.05).  Blend, 
week 0 scaffolds recovered better than week 6 and week 12 (p<0.05).  Degradation of 
the blended or co-spun groups drastically reduced the scaffolds’ ability to recover, as 
compared to other groups. 
 
DISCUSSION 
A comparison among the groups and their outcome measures was developed 
to determine the optimal scaffold design (Table 3.2).   
Fiber diameter, pore size, porosity, and their interconnected relationship affect 
cell response.  Submicron PCL fibers, in a range from 0.25-2 µm have been shown to 
improve cell attachment and proliferation due to the increased surface area that 
enhanced protein binding 
110
.  However, this relationship has not been seen with other 
polymers 
110
.  The scaffolds in the current study exhibited fiber diameters in the 
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micron range, with PCL-only scaffolds exhibiting a slightly lower fiber diameter than 
other groups.  Fiber morphology and diameter can be tuned with the electrospinning 
fabrication process (e.g., solution concentration, solution conductivity, needle to 
collector distance, ambient conditions) 
90
.  In our process, these parameters were 
empirically selected to produce uniform submicron-micron fibers in the range of 0.5-
1.5 µm (data not shown).  However, fiber morphology altered significantly after 
sterilization, specifically in the case of PLGA fibers, which appeared to have melted 
after sterilization (flattened appearance in SEM images).  This phenomenon is not 
mentioned greatly in the electrospinning literature, except for one study that found 
that ethylene oxide can damage fragile structures found in electrospun materials 
92
.  
Further investigation is needed to determine how the ethylene oxide sterilization 
process can be altered (e.g., concentration, temperature, humidity, time) to preserve 
scaffold architecture or to determine better sterilization methods.  
The blending of two polymer prior to electrospinning created a distinctive 
fiber morphology which could be due to phase separation where the two polymers 
assumed distinct spatial organization with-in one fiber when electrospun, where the 
PCL component could be the spindle-like fibers in the interior of the fibers and the 
PLGA component filling around through PCL fibers.  The difference in polymer 
properties (e.g. conductivity) could have affected how the two polymers electrospun 
together.  The unique fiber morphology created by polymer blending could be used 
beneficially in specific tissue applications.   
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Porosity is another important factor that affects cell infiltration and diffusion.  
All of the groups, except for the PLGA-only group, at some point during degradation 
had the recommended range of 70-90% porosity 
110
.  All groups became significantly 
more porous after 6 weeks due to the degradation of the PLGA component.  The 
Gradient+Ring group had a decline in porosity due to the retention of the solid PCL 
ring.  To obtain more accurate porosity measurement, other techniques could be 
employed (e.g., gas adsorption or flow porosimetry) 
38
, although our work with 
microCT revealed that the submicron pore sizes in electrospun materials were not 
detectable.
62
  Techniques to increase porosity can be employed with electrospinning, 
like salt leaching, sacrificial-fiber incorporation, 3D printing, or phase separation.
62
  
The PCL ring’s porosity could be increased to allow for cellular infiltration prior to 
degradation; however, mechanical properties would need to be maintained with the 
increase in porosity.   
Molecular weight change and mass loss of the scaffolds were used to assess 
how the tunable properties (i.e., polymer mixing and layering) affect degradation.  
Since static degradation conditions were employed, as compared to dynamic 
mechanical loading, chemical degradation was the primary degradation mechanism.  
PCL and PLGA degrade through hydrolysis of the aliphatic ester linkages and 
undergo bulk erosion.
123
  We hypothesized that fiber mixing (Co-spun, Gradient, and 
Gradient+Rings) would slow PLGA degradation due to limited diffusion of water to 
the internalized PLGA fibers.  Indeed, the molecular weight profile for PLGA was 
slightly higher in combination groups as compared to PLGA-only (variation in MW in 
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MALS data due to signal overlap).  The decrease in PLGA molecular weight had a 
direct impact on suture retention strength, and less so on tensile or compressive 
properties.  The dispersion of PLGA throughout the bulk of the scaffold (Blend and 
Co-spun) resulted in worsened tube flattening recovery, indicating that a thick PCL 
layer contributed to the elastic recovery of the scaffolds.  Should the mechanical or 
drug delivery properties need to be tailored, the degradation of the PLGA can be 
controlled by LA/GA ratio, molecular weight, and shape/structure of matrix. 
Desired mechanical properties for scaffolds usually rely on mimicking 
physiological conditions or empirical data derived from native tissue, although 
biomimicry may not necessarily result in functional in vivo performance.  Tensile 
properties in the circumferential direction have no analog in vivo, besides 
inhalation/exhalation force, which will be discussed in the burst pressure section.  
Tracheal cartilage, crucial to the structural integrity of the trachea, exhibits a 
nonlinear stress-stain behavior with tensile forces from 0.02 to 0.01 N (porcine 
cartilage) 
119
.  The superficial zone of human tracheal cartilage (collagen dense 
region) resists tension, while the inner layer (proteoglycan rich) resists compression 
(equilibrium tensile modulus was 13.6 ± 1.5 MPa for abluminal superficial zone and 
4.6 ± 1.7 MPa for middle zone) 
95
.  Rabbit tracheal cartilage exhibits an ultimate 
tensile strength of 4.08 ± 0.96 x 10
2
 kPa and elastic modulus of 3.5
  
± 1.1 x 10
2
 kPa 
141
.  Comparing these data to our data, our scaffolds exceeded the Young’s modulus 
of the native rabbit trachea, except for PLGA-only.  Gradient+Rings scaffolds 
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possessed an equilibrium modulus similar to human tracheal tissue (in the abluminal 
superficial zone).     
 Physiological expiration and inspiratory pressures for adults and kids are in 
the range of 60-150 mm H2O (or 0.853-2.133 psi) 
131
.  Bursting strength of the 
porcine trachea has been reported to be 180 mmHg (3.48 psig) in the pharyngeal 
portion (dorsal or top of trachea) and progressively decreased down the trachea length 
to 110 mmHg (2.13 psig) in the tracheal carina (ventral or bottom of trachea before 
bifurcation) 
104
.  Our implant was tested in its tubular form, not sutured into a native 
trachea.  Testing the implant alone revealed that the scaffolds in all of the groups far 
exceeded any forces exerted by breathing or pressures required to burst native porcine 
tracheas.  If more complex in vitro characterization were to be employed, dynamic 
degradation conditions could mimic breathing forces and would likely speed 
degradation of the scaffolds thus altering mechanical properties.
140
  In vivo, if any 
failure occurred it would likely be at the suture line, thus future testing could involve 
testing the scaffolds sutured into cadaveric tracheas.   
 Suture retention is crucial as failure at the suture line would be catastrophic.  
Maximum suture retention in an anastomosis model using a single-interrupted PDS 
suture, placed around the circumference of the trachea, was 123 N (sheep trachea) 
9
.  
Native trachea suture retention for our testing method was not found in the literature.  
Our suture holding capacities were at a much lower range than an anastomosis model, 
due to the inequivalent comparison of one single-interrupted suture (our testing) to a 
series of single-interrupted sutures (anastomosis model).  The PLGA-only and Blend 
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had poor suture retention strengths, while the other groups performed in a range of 
20-70 MPa.   
Tube flattening or radial compression of the trachea is comparable to a 
situation where an external force compressed the airway (i.e., during trauma).  
Porcine tracheas withstand compression (across the diameter) to 50% strain, which 
results in an average radial pedestal force of 10 N 
104
.  The rabbit trachea had a 
compressive strength of 2.1 N at 50% compressive displacement 
41
.  Our scaffolds 
were tested to 100% strain (completely flattened), with that in mind, our 
Gradient+Rings scaffolds far exceeded the native porcine and rabbit trachea’s ability 
to resist radial force.  The PCL-only and Bilayer scaffolds had an average tube 
flattening force of 3.8 N, which could be comparable to the rabbit trachea 
compressive strength.  This tube flattening property of the scaffolds will be crucial to 
tracheal patches that exist for the purpose of holding open a stenosed trachea that has 
been opened to widen the airway. 
 The application of these materials will impact interpretation of the results.  
Tracheal materials can be implanted in small, patch-type defects and in long, 
circumferential defects.  Each scenario demands slightly different properties of our 
scaffolds and should be considered when utilizing our data and materials.  
Additionally, these scaffolds could have other applications, specifically vascular and 
intestinal tissue engineering.   
In conclusion, we evaluated the fiber morphology, polymer degradation, 
porosity, and mechanical properties of seven variations of our fibrous trachea 
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scaffolds under in vitro degradation conditions. While all scaffolds had at least one 
favorable characteristic, the graded scaffolds with rings had improved tensile and 
radial compression properties, largely due to the 3-D printed PCL rings.  And we can 
assume that the rings would have an impact on burst pressure if testing could exceed 
30 psig.  The fibrous PCL component also plays an important role in recovery 
properties and suture retention, with the tensile equilibrium moduli and percent 
recovery after tube flattening being much higher in the PCL containing groups.  
Additionally, the fibrous materials are an excellent suture holding substrate.  We can 
conclude that the addition of a structural and flexible fibrous component is crucial for 
tracheal scaffolds to recapitulate the function of the native trachea cartilage and 
connective tissue.  Therefore, our reinforce, fibrous scaffolds have the potential to be 
utilized for trachea tissue engineering applications, after further in vitro and in vivo 
testing.    
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CHAPTER 4:  Electrospun Fibrous Scaffolds for Tracheal Defect 
Repair: Pilot Studies 
 
ABSTRACT 
Current treatments for tracheal stenosis do not predictably return normal 
function to the trachea, thus new treatment solutions may be useful.  Synthetic tissue 
engineered scaffolds could provide otolaryngologists with an important new 
technique, if it can be easily implemented.  We undertook three preliminary 
investigations during which polymeric electrospun fibrous scaffolds were sutured into 
induced defects in rabbit tracheas.  The studies utilized 1) polycaprolactone (PCL) 
scaffolds implanted in a patch-type application, 2) trilayer gradient scaffolds of 
polylacticcoglycolic acid (PLGA) and PCL with encapsulated growth factors 
implanted in a patch-type defect, and 3) bilayer gradient scaffolds with incorporated 
rings in a circumferential segment-type defect.  In the patch-type defects, the animals 
were thriving, showing no signs of infection or air leakage into their wounds, and no 
signs of respiratory distress.  CT scans and histology confirmed that the airways 
remained patent, with some cell infiltration and re-epithelialization on the scaffolds 
using standard tissue processing and staining.  The current study demonstrates for the 
first time that tracheal defect repair with biodegradable polymeric scaffolds with 
fibers is feasible and life-sustaining in an animal model.  In the circumferential 
segment-type defect, severe stenosis caused fatalities in all animals.  Scaffold use in 
this model should be redesigned, and the surgery method should be reassessed.  
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INTRODUCTION 
Tracheal stenosis is a rare but often fatal disease with a mortality rate as high 
as 77%.
26
  Current treatments for tracheal stenosis alleviate the effects of the stenosis 
using specialized surgical procedures (e.g., slide tracheoplasty) or cartilage 
augmentation of a focal region of stenosis.  There is not, however, a treatment that 
completely returns normal function to the trachea.
32
  Furthermore, some donor site 
morbidity occurs with augmentation techniques, and size or shape mismatches are not 
uncommon.  Tissue engineering has the potential to create effective replacement 
trachea-like tissue for procedures like laryngotracheal reconstruction, and may 
circumvent these problems.     
Fibrous electrospun materials have been used in various realms of tissue 
engineering, but have not been extensively utilized in trachea regeneration (Brizzola 
et al.
12
 conducted a trachea study with unaligned fibers).  Electrospinning is one of 
the most efficient fabrication techniques to create microscale and nanoscale fibers.  
Electrospun fiber based materials create favorable microenvironments that closely 
mimic native extracellular matrix (ECM) and support cell attachment, differentiation, 
and growth.
71
  Circumferentially aligned fibers further mimic the collagen in native 
tracheal cartilage, where the outer superficial zones of cartilage have 
circumferentially aligned collagen fibers (which are active in tensile resistance and 
combat inward collapse).
95
  These scaffolds are biomimetic in their structure, and 
they are based on synthetic materials that are not reliant on donor tissue for tracheal 
regeneration.
99, 106, 133
  Thus, the theoretical benefits of electrospun fibrous scaffolds 
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are their ability to allow tissue ingrowth, their lack of reliance on donor tissue, and 
their ability to be created in a variety of sizes and shapes. 
The objective of these studies was to demonstrate the feasibility of our 
concept.  We hypothesized that cellular infiltration and a favorable tissue response to 
the scaffold would be observed.  A feasibility study of this nature is warranted in 
order to demonstrate a promising new technology, and to establish a foundation for 
larger studies, if successful.  Three pilot studies were performed on:  1) 
polycaprolactone (PCL) scaffolds implanted in a patch-type application, 2) trilayer 
gradient scaffolds of polylacticcoglycolic acid (PLGA) and PCL with encapsulated 
growth factors implanted in a patch-type defect, and 3) bilayer gradient scaffolds with 
incorporated rings in a circumferential segment-type defect (Figure 4.1).   
 
METHODS 
Material fabrication   
Using a custom designed electrospinning apparatus, 2 mm thick electrospun 
fiber sheets were fabricated following a slightly modified protocol established in a 
previous publication.
57
  Briefly, liquid polymeric solutions were mixed and placed in 
a 20 mL syringe and fitted into a programmable syringe pump (PhD Ultra, Harvard 
Apparatus) set to extrude the solution at a set flow rate.  As the solution was extruded 
through a charged 20 gauge needle, the charged polymer was drawn from the needle 
tip to the rotating cylindrical stainless steel mandrel.  The electrospun tube was 
removed from the collecting rod by cutting with scalpel (biomaterial sheet observed 
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in Figure 4.2, sterilized using ethylene oxide, and aired in a fume hood for 24 hours.  
Safety precautions, personal protective equipment and a well ventilated working 
environment were used when handling toxic solvents.     
For the first pilot study (2 rabbits), we used a 23% w/v solution consisting of 
polycaprolactone (Intrinsic viscosity= 1.0-1.3 dL/g, Lactel) in methylene chloride 
(Fisher Scientific).  Extrude the solution at 1.3 ml/hr and charged to 20 kV (Glassman 
High Voltage, High Bridge, NJ) onto a 6.35 mm diameter cylindrical stainless steel 
mandrel rotating at 10,000 rpm.          
For the second pilot study (6 rabbits), a 18% w/v polycaprolactone (PCL; 
intrinsic viscosity 1.0-1.3 dL/g, LACTEL, Birmingham, AL) solution in 
dichloromethane (DCM; Fisher Scientific, Hampton, NH): dimethylformamide 
(DMF) (80:20) and a 30% w/v poly(D,L-lactide-co-glycolic acid) copolymer (PLGA; 
50:50 lactic acid : glycolic acid, acid end group, MW 50,000 Da, intrinsic viscosity 
0.35 dL/g, Evonik Industries, Birmingham, AL) solution in DCM:DMF (80:20).  
Extruded the solution at 5 ml/hr and it was charged to 20 kV (Glassman High 
Voltage, High Bridge, NJ) and collected on a rotating cylindrical stainless steel 
mandrel (6.35 mm diameter; 10,000 rpm measured with tachometer).   
To create the protein-loaded PLGA solutions, transforming growth factor beta 
3 (TGF-B3; Peprotech, Rocky Hill, NJ) and epidermal growth factor (EGF; 
Peprotech, Rocky Hill, NJ) were reconstituted in 0.1% bovine serum albumin (BSA) 
in phosphate buffered saline (PBS).  The reconstituted protein solutions were 
individually mixed with the PLGA solutions to reach a final loading ratio of 1.5 ug of 
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TGF-B3 or 6.0 ug of EGF per 1.0 mg of PLGA.  The final mixtures were then 
sonicated over ice (50% amplitude, 20 s).  The solutions were electrospun 
immediately after preparation. 
To create the sharp interface group, 6 mL of PLGA was electrospun on to the 
collecting mandrel (0.5 layer thickness), then 10 mL of PCL was electrospun on to 
the PLGA layer (1 mm layer thickness), and finally 6 mL of PLGA was electrospun 
on to the PCL layer (0.5 mm layer thickness).  The final wall thickness was 2 mm. 
To create the gradient interface group, 2 mL of PLGA was electrospun (0.25 
mm layer thickness), then 2 mL of PLGA and 2 mL of PCL was simultaneously 
electrospun on to the PLGA layer (0.5 mm layer thickness), followed by 4 mL of 
PCL electrospun on to the PLGA/PCL layer (0.5 mm layer thickness), then 2 mL of 
PLGA and 2 mL of PCL was simultaneously electrospun on to the PCL layer (0.5 
mm layer thickness), and finally 2 mL of PLGA was electrospun on to the 
PLGA/PCL layer (0.25 mm layer thickness).  
 To create the scaffolds for the circumferential defect study (4 rabbits) (Figure 
4.12), the  using a 7 wt% polycaprolactone (PCL; intrinsic viscosity 1.0-1.3 dL/g, 
LACTEL, Birmingham, AL) solution in hexafluoro-2-propanol (HFIP; Oakwood 
Chemical; Columbia, SC) and a 14 wt% poly(D,L-lactide-co-glycolic acid) 
copolymer (PLGA; 50:50 lactic acid : glycolic acid, acid end group, MW 50,000 Da, 
intrinsic viscosity 0.35 dL/g, Evonik Industries, Birmingham, AL) solution in HFIP.  
The solution was extruded at 5 mL/hr and the 20 gauge needle was charged at +12 kV 
(Glassman High Voltage, High Bridge, NJ) and the rotating cylindrical stainless steel 
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mandrel (7 mm diameter) was charged to -6 kV.   To create the gradient interface 
group with circumferential rings, 6 mL of PCL was deposited, the PCL or Bioglass 
Rings rings (PCL-created by mixing 15 w/v% PCL in 1:1 DCM:DMF solution, 
pouring solution into flat plate and allowing solvent to evaporate forming a polymer 
sheet; rings were cut to 1-2 mm width, approx. 1.5 mm thickness; Bioglass provided 
by MO-SCI, MO)  were wrapped around the cylindrical stainless steel mandrel at 3-4 
mm intervals, 6 mL of PCL was deposited over the rings, followed by co-spinning 8 
mL of PCL and 8 mL of PLGA to create the gradient layer, followed by 12 mL of 
PLGA.    
Surgical procedure   
Animal experiments were approved by the Institutional Animal Care and Use 
Committee of the University of Kansas (2 rabbit study= #175-06, 6 rabbit study= 
#175-13, 4 rabbit study= #175-15).   
For the first pilot study (2 rabbits), prior to the procedure, routine antibiotics 
and analgesics were administered to male New Zealand White rabbits (9-10 lbs) 
(n=2), and general anesthesia was induced with a combination of ketamine (40 
mg/kg) and xylazine (5 mg/kg).  The surgical sites were cleaned and disinfected after 
removal of hair.  Once ready, the rabbits were laid in the supine position and an 
incision along the neck region was made to access the trachea.  In each rabbit, an 
elliptical defect (approximately 0.5 by 2 cm with the long axis oriented vertically 
along the main axis of the trachea) was created in the tracheal wall and the 
biomaterial graft was placed, partially overlapping the tracheal wall to form an 
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appropriate seal using 4-0 polydioxanone suture material.  The scaffold material was 
sized to 1 by 2.5 cm, and cut from a sheet of the polymer in the operating room.  The 
process is illustrated in more detail in Figure 1.  Additionally, a second implant (1 by 
1 cm square) was placed subcutaneously along the back of the animal.   
For the second pilot study (6 rabbits), following stable general anesthesia, the 
surgical sites of male New Zealand White rabbits (9-10 lbs) (n=6) were cleaned and 
disinfected after removal of hair.  The bare neck region was disinfected with three 
alternate scrubs of betadine and 70% ethanol and then draped. Only strict aseptic 
techniques and sterile instruments were used, and the surgeon wore sterile gowns, 
masks, and head covers.  Once ready, the rabbits were laid in the supine position and 
an incision along the neck region was made to access the trachea.  In each rabbit, an 
elliptical defect (approximately 0.5 by 2 cm with the long axis oriented vertically 
along the main axis of the trachea) was created in the tracheal wall and the 
biomaterial graft was placed, partially overlapping the tracheal wall to form an 
appropriate seal using 4-0 polydioxanone suture material.  The scaffold material was 
sized to 1 by 2.5 cm, and cut from a sheet of the polymer in the operating room.    
For the third pilot study (circumferential defect in 4 rabbits), the procedure 
was very different than the patch implantation illustrated above.  A ventral midline 
cervical incision was made, including identification and division of the strap muscles.  
The cervical trachea was then accessed.  A defect was marked out on the wall of the 
trachea with an approximate size of 1 centimeter segment of trachea.  The defect was 
centered approximately 2 centimeters below the cricoid cartilage.  The marked area of 
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trachea was removed with sharp dissection, the ET tube was removed quickly, and 
the resulting void was replaced with a tube of electrospun graft approximately the 
same diameter as the rabbit’s native trachea, with overlap on both ends to ensure a 
seal.  Absorbable polydioxanone suture (size 4-0) was used for this step.  The wound 
was losed in layers using polyglycolic acid absorbable suture in the muscle layer and 
the subcuticular or skin closure layer.   
Bronchoscopy  
Bronchoscopy was performed at 3 and 4.5 weeks for the third pilot study.  A 
video-endoscopy system consisting of a bronchoscope (10020ATA; Hopkins 
Telescope, 0°, 2.9 mm, 30 cm; Karl Storz Endoskope; Tuttlingen, Germany) and a 
video processor coupled to a light source (20045020; TelepackX; Karl Storz 
Endoskope; Tuttlingen, Germany) was used for bronchoscopic evaluation.  The 
degree of reepithelialization over the scaffolded region and appearance of stenotic 
regions of the trachea were evaluated with a bronchoscope.  Procedures were done 
under anesthesia and analgesics were given post-procedure. 
CT scan  
Seven weeks after implantation, the first pilot study animals’ laryngotracheal 
complex and subcutaneous implant were harvested following an approved protocol 
for euthanasia.  Prior to storage in formalin and histological staining, the excised 
tracheas were imaged using a CT scanner system (Siemens Somatom Sensation 64 
high resolution scanner) and reconstructed using Inspace software (Siemens).   
microCT analysis   
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After completion of the second and third pilot study, tracheas were excised and 
fixed in 10% neutral buffered formalin.  To aid in soft tissue visualization in the 
microCT analysis, the fixed tracheas were soaked in 40% Hexabrix (Covidean)/60% 
PBS for 20 hours.1  All tracheas were secured in a vertical position during scanning, 
so that the microCT scanner produced transverse cross-sectional slices.  To prevent 
dehydration during scanning, the tracheas were placed in a tube, with PBS at the 
bottom and sealed with parafilm.  All scans were performed using a 3D X-ray 
imaging system (Xradia MicroXCT-400, Pleasanton, CA) at 40 kV, 8 W, 2 second 
exposure time, 0.5x objective magnification.  For high quality images, 1600 
projections were collected with multi reference images selected at 10 images every 
400 frames for a total acquisition time of 2.5 hours.  After acquisition, the images 
were manually reconstructed using the Xradia software.  The center shift and beam 
hardening were determined.  
To determine percent stenosis, the diameter of the scaffolded and normal regions 
of trachea were measured in the CT software.  The scaffolded trachea diameter (Ds) 
was divided by normal trachea diameter (Dn) and subtracted by 1, i.e., Stenosis = 1 – 
(Ds/ Dn). 
Histological analysis   
The tracheas and subcutaneous implants were then placed in formalin.  The 
samples were cryogenically sectioned, and stained with hematoxylin and eosin 
(H&E).  For the second study, hematoxylin and eosin (H&E) and safranin O/fast 
green were run.  Immunohistochemical analysis for collagen I (CI), collagen II (CII; 
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10 ug/mL; AF5710, Acris Antibodies, San Diego, CA), and actin was done using a 
secondary antibody peroxidase system kit (ABC Elite Mouse IgG kit, Vector Labs, 
Burlingame, CA).  The presence of antibody was visualized with a AEC peroxidase 
substrate producing a red color (Vector Labs).  As a positive control, trachea without 
the scaffold was stained.  As a negative control, the normal staining protocol was 
followed, excluding the primary antibody.  Photomicrographs were taken of 
representative sections of the interfaces between the polymer and the animal’s native 
tissue. 
  
RESULTS 
Mortality 
The implantation of the scaffolds was straightforward, with the scaffolds 
being easily cut into the desired elliptical shape in the operating room and sutured 
into the induced defect (Figure 4.3).  The segmental defect was a more challenging 
surgery than the patch-defect surgeries (Figure 4.13).  Throughout the course of the 
first and second pilot studies, the rabbits did not display any signs of distress and ate 
and breathed normally, with the exception of slight wound opening in one rabbit in 
the second pilot study.  In this event, staples were used to close the wound and 
antibiotics were administered (Baytril).    
The subjects in the third study exhibited more adverse reactions.  Throughout 
the 6 weeks of the study, all of the rabbits displayed signs of distress.  In the event of 
an adverse reaction (i.e., labored breathing, coughing, weight loss, stridor, death), the 
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rabbit underwent bronchoscopic evaluation, vital sign monitoring, more frequent 
monitoring, and administration of dexamethasone to alleviate inflammation and 
stenosis.  If the animal’s condition was rapidly declining and no intervention methods 
were available, euthanasia was determined to be the best course of action.  There was 
0% survival, with Bioglass subject 1 dying 1 day post-op, Bioglass subject 2 dying 17 
days post-op, PCL subject 1 and 2 were euthanized 30 days post-op.      
Bronchoscopy 
The third study subjects underwent bronchoscopy.  PCL group tracheas were 
analyzed after excision and fixation.  Bronchoscopy images revealed that Subject 1 
had an open airway and Subject 2 had a blocked airway and could not pass endoscope 
through.  We forced a suction tube through the blockage (Figure 4.14).  The Bioglass 
group, subject 3 bronchoscopy revealed severely narrowed trachea on the proximal 
end of graft.  And Bioglass group, subject 4 bronchoscopy revealed narrowing of the 
trachea on the distal end of the graft.  The image also shows yellow region which is 
the graft (Figure 4.14).   
Gross morphological observations 
At the time of harvest, the gross morphological observations of the tracheas 
revealed the presence of polymer and tissue growth around the scaffold (Figure 4.4, 
Figure 4.7).   
The third study, Bioglass, Subject 1 necropsy revealed that the trachea was 
filled with froth/foam, and the lungs were more congested that what normally see 
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post-mortem.  Bioglass, Subject 2 necropsy nothing significant noted in necropsy 
(bowel and heart looked normal, did not look down trachea).      
CT and histology 
For the first study, the CT scans revealed that the airway was widely patent, 
and the 3-D reconstructions suggested no obvious new cartilage formation (Figure 
4.5).  The histological sections of the tracheas illustrated several key findings: (1) The 
lumen of the scaffold was covered with normal ciliated respiratory epithelium, (2) 
various cells were dispersed throughout the scaffold, with multinucleated giant cells 
observed among electrospun fibers, (3) there was no cartilage-like tissue within the 
scaffold (Figure 4.6).   
For the second study, the microCT scans revealed acceptable narrowing of the 
trachea through the grafted sections, but not severe stenosis.  Tissue sections revealed 
the presence of PCL and almost complete resorption of PLGA, as expected.  There 
was coverage of the outer surfaces with a cartilage-like tissue (evidenced by collagen 
II immunohistochemistry) (Figure 4.10, Figure 4.11), and with normal ciliated 
epithelium lining the lumen of the scaffold in all groups.  These results with the new 
preliminary study have clearly demonstrated an improvement over the PCL-only 
scaffold, with intense collagen II immunostaining of the regenerated cartilaginous 
region. 
Tracheal diameter was observed to decrease in the scaffold regions across all 
groups.  The diameters appeared to decrease by approximately 35% (1-2 mm) (Figure 
4.8, Figure 4.9).  Although narrowing occurred in the scaffold, rabbits were able to 
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respire without difficulty.  The addition of tougher materials, like bioglass ribbons, to 
the scaffold could alleviate the slight collapse induced by the removal of cartilage 
ring support.  Between groups, no differences in microCT images were observed.  A 
summary of diameters were: Group 1 (Trilayer):  diameter=4.4 mm, normal 
diameter=6.8 mm, 35% decrease in diameter; Group 2 (Trilayer w/GF):  
diameter=3.5 mm, normal diameter=5.1 mm, 32% decrease in diameter; and Group 3 
(Gradient w/GF): diameter=3.2 mm, normal diameter=5.5 mm, 42% decrease in 
diameter.  
For the third study, the microCT scans revealed significant stenosis at the 
proximal and distal ends of the implant (located at anastomosis sites) (Figure 4.15).     
 
DISCUSSION 
The electrospun scaffolds maintained the shape and airtight seal of the trachea 
in the first two pilot studies.  Keeping the airway open is crucial for a tracheal 
prosthesis to perform properly, which has been a major issue in prior tracheal tissue 
engineering studies.  Further mechanical testing of these scaffolds is needed, but this 
in vivo study demonstrated effective mechanical performance of the scaffold material.   
In the first pilot study, the presence of multinucleated giant cells could 
indicate a multitude of issues; however, we believe that the presence of these cells 
within our scaffold indicates “non-immune” chronic inflammation.  These cells are 
reactive to relatively inert foreign materials (e.g., suture fragments) and can be 
classified as foreign body granulomas (as opposed to immune granulomas.)  
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Multinucleated giant cells are commonly observed in implanted tissue engineered 
scaffolds.
3
  These cells are known to be mediators in biomaterial degradation
4
 and 
indicators of a foreign body reaction.  Within this 7 week time period, the rabbit 
appeared to tolerate the scaffolds with only a low level inflammation response based 
on the presence of the multinucleated giant cells.  However, further evaluation of the 
degree of inflammation and longer time points in follow-up studies will better 
confirm the true immunogenic properties of the scaffolds. 
The native rabbit trachea possesses a distinct cartilaginous character.
130
  
Replicating this cartilaginous component within a tracheal repair site would seem to 
be desirable.  Cellular infiltration and fibrous-type tissue were observed within the 
scaffolds in the first two studies, which may indicate a favorable environment for 
chondrogenesis.  No new cartilage formation in the histological evaluation of our 
specimens was a shortcoming of the first pilot study.  Utilizing alternative techniques 
like including growth factors (e.g., transforming growth factor-β3) could provide the 
desired degradation kinetics, chemotactic effects, and accelerated tissue growth for 
cartilage tissue regeneration in future tracheal defect repair studies.  And we did 
observe increased CII staining on the external surface of the implant in the second 
pilot study.  Further analyses of techniques to improve chondrogenesis are needed.  
Chondrogenesis in scaffolds is possible, as observed in other tissue engineering 
studies,
45, 59, 88
 but it remains a major challenge to achieve robust chondrogenesis.   
In the segmental, circumferential study, the defect creation and reanastomosis 
of a tracheal scaffold was highly traumatic and induced granulation tissue that 
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occluded the airway.  Different surgical techniques and scaffold design are needed to 
improve outcomes in future studies (Figure 4.16).  Instead of fitting the scaffold over 
the trachea, we should place the scaffold inside the trachea to block inflamed tissue 
from gathering in the trachea lumen (causing stenosis).  The limitation of this 
technique is a reduction in the scaffold diameter, which significantly encroaches on 
the airway in a small animal model (or patient) with a small airway.  Re-designing the 
scaffold to accommodate for this is necessary (Figure 4.16).  Other re-design 
considerations include making the adaptor portion of the scaffold out of a 
woven/mesh material, similar to a metallic stent.  Short-term use of steroids or other 
anti-inflammatories in the scaffold or delivery upon implantation could be another 
technique to reduce early inflammation associated with defect creation.   
  We investigated alternative surgical techniques to join scaffold and trachea, 
and we made the following observations.  End-to-end anastomosis resulted in a 
misalignment of the trachea and scaffold (Figure 4.16).  When sutured together, the 
scaffold was partially pulled inside the trachea and partially outside the trachea.  This 
is demonstrated in the endoscopy image, where the trachea is observed in the scaffold 
(on the left side of the image).  We investigated scaffold inside trachea suturing.  
Scaffold diameter is crucial, where the scaffold should seamlessly fit inside the 
trachea without buckling and folding.  We looked at hemi-circular scaffolding, and 
we determined that removing a hemi-circular patch of the trachea completely disrupts 
the mechanical stability of the trachea.  As a result, the remaining trachea tissue 
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cannot support suturing of the scaffold material.  In conclusion, scaffold inside 
trachea suturing is the ideal technique. 
  In conclusion, this preliminary study revealed that a polymeric, electrospun 
scaffold implanted in the trachea allowed for tissue overgrowth and survival of the 
rabbits (except for circumferential defects), demonstrating feasibility of this 
technology and a platform for expanded studies with more advanced designs.   
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CHAPTER 5:  Functional reconstruction of tracheal defects by 
protein-loaded, cell-seeded, fibrous constructs in rabbits 
 
ABSTRACT 
Tracheal stenosis is a life-threatening disease and current treatments include 
surgical reconstruction with autologous rib cartilage.  We propose using a sustainable 
implant, composed of a tunable, fibrous scaffold with encapsulated chondrogenic 
growth factor (TGF-B3) or seeded bone marrow mesenchymal cells (BMSCs).  In 
vivo functionality of these constructs was determined by implanting them in induced 
tracheal defects in rabbits for 6 or 12 weeks.  Our scaffolds maintain functional 
airways in a majority of cases, with the cell-seeded group having an improved 
survival rate and the acellular group had a higher occurrence of more patent airways.  
The BMSC group had a more severe accumulation of immune cells over the graft, 
while also exhibiting more normal epithelium, subepithelium and cartilage formation.  
This leads us to conclude that a simple, acellular scaffold is a viable option for 
tracheal tissue engineering, with the intraoperative addition of cells being an optional 
variation to the scaffolds.    
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INTRODUCTION 
Laryngotracheal disorders resulting in airway obstruction, although rare, can 
cause significant morbidity and can be life threatening.  These disorders are the result 
of congenital (laryngo/tracheomalacia, congenital subglottic stenosis) or acquired 
(prolong intubation, traumatic injury, tracheotomy, tumors) causes.  The estimated 
incidence of stenosis in post intubation or tracheotomy patients is 10-20% with only 
1-2% being symptomatic or having severe stenosis (estimated 4.9 severe stenosis 
cases per million per year in the general population.) 
79, 144
.  Due to the congenital 
occurrences and increased survival of pre-mature infants requiring prolonged 
intubation, the pediatric population makes up a significant portion of patients 
requiring treatment. 
Treatment options include balloon dilation, laser surgery, stenting, and 
surgical resection and reconstruction; with reconstruction being the preferred 
alternative for severe stenosis, though there are limitations to this treatment.  
Laryngotracheal reconstruction (LTR) involves augmenting the stenotic region with 
autologous costal cartilage.  Specialized surgical technique and an invasive, multi-site 
surgery are required for this procedure.  Thus, an off-the-shelf tissue-engineered 
product is needed that would replace the need for autologous tissue and eliminate the 
challenges for the surgeon and patient.   
Various tissue engineered trachea replacements exist
87
, including human trials 
with decellularized donor tissues re-cellularized with autologous cells
66
 and non-
degradable polypropylene scaffolds coated with natural materials.
83
  Approaches 
 
79 
utilizing degradable synthetic materials are gaining popularity due to the limited 
availability, specialized preparation, and storage of donor tissues, and the limited 
regenerative capacity of non-degradable materials.
16
  We endeavor to use biomimetic, 
polymeric scaffolds for trachea repair, utilizing electrospun poly-lactic-co-glycolic 
acid (PLGA) and polycaprolactone (PCL) graded, biphasic scaffolds reinforced with 
PCL rings for tracheal defect repair.  Our hypothesis is that the scaffold will provide 
an airtight, biocompatible prosthesis with potential for cartilage-like tissue 
replacement.  Our preliminary pilot studies in rabbits indicated that the scaffolds were 
functional in patch-type tracheal defects (not published).  Thus, a larger study in vivo 
study is needed to establish statistically significant efficacy.  Three groups were 
designed for the current study: 1) the gradient scaffold with reinforced rings, 2) the 
scaffold with TGF-β3 encapsulated in the PLGA, and 3) the scaffold with rabbit bone 
marrow mesenchymal stem cells (BMSCs) seeded intraoperatively (Figure 5.1).  The 
objective of the current study was to supplement the pre-clinical data available for 
tracheal tissue engineering.  The following paper includes a description of the 
materials and materials used to create the scaffolds and surgically implant them, the 
results will further highlight the more pertinent findings from our study, and the 
discussion will assess the significant and implications of the data.    
 
MATERIALS AND METHODS 
Material fabrication 
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Using a custom designed electrospinning apparatus, 2 mm thick electrospun 
fiber sheets were fabricated following a slightly modified protocol established in a 
previous publication.
58
  A 7 wt% polycaprolactone (PCL; intrinsic viscosity 1.0-1.3 
dL/g, LACTEL, Birmingham, AL) solution in hexafluoro-2-propanol (HFIP; 
Oakwood Chemical; Columbia, SC) and a 14 wt% poly(D,L-lactide-co-glycolic acid) 
copolymer (PLGA; 50:50 lactic acid : glycolic acid, acid end group, MW 50,000 Da, 
intrinsic viscosity 0.35 dL/g, Evonik Industries, Birmingham, AL) solution in HFIP.  
The solutions were placed in 20 mL syringes and fitted into programmable syringe 
pumps (PhD Ultra, Harvard Apparatus, Holliston, MA) set to extrude the solution at 5 
ml/hr.  As the solution was extruded through a charged 20 gauge needle (+10 kV, 
Glassman High Voltage, High Bridge, NJ), the charged polymer was drawn from the 
needle tip to a negatively charged (-6 kV) rotating cylindrical stainless steel mandrel 
(6.35 mm diameter).  Safety precautions, personal protective equipment and a well 
ventilated working environment were used when handling toxic solvents.       
To create the graded, biphasic group, 8.33 mL of PCL was electrospun (0.34 
mm layer thickness), then PCL rings (created by mixing 15 w/v% PCL in 1:1 
DCM:DMF solution, pouring solution into flat plate and allowing solvent to 
evaporate forming a polymer sheet; rings were cut to 1-2 mm width, approx. 1.5 mm 
thickness.) were affixed to the PCL and arranged 3-4 mm apart along the length of the 
cylindrical stainless steel mandrel.  Another 0.34 mm layer of PCL was electrospun 
over the rings, thus encapsulating the rings between layers.  6.67 mL of PLGA and 
PCL (total of 13.33 mL total polymer) was simultaneously electrospun on to the PCL 
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layer (0.67 mm layer thickness), followed by 8.33  mL of PCL electrospun on to the 
PLGA/PCL layer (0.67 mm layer thickness). 
To create the protein-loaded PLGA solutions, transforming growth factor beta 
3 (TGF-β3; Peprotech, Rocky Hill, NJ) were reconstituted to 1 mg/mL with 10 mM 
citric acid (251275; Sigma; Milwaukee, WI)  and further diluted to 0.8 mg/mL with 
0.1% bovine serum albumin  (BSA; BP9706; Fisher Scientific; Waltham, MA) in 
phosphate buffered saline (PBS; P5368; Sigma; Milwaukee, WI).  The reconstituted 
protein solutions were individually mixed with the PLGA solutions to reach a final 
loading ratio of 30 ng of TGF-β3 per 1.0 mg of PLGA (approx. 126 µg of TGF-β3 
per scaffold).  The final mixtures were then sonicated over ice (50% amplitude, 20 s).  
The solutions were electrospun immediately after preparation. 
Once the 2 mm wall thickness was achieved, the electrospun tubes were 
removed from the collecting rod, lyophilized for 24 hours, sterilized using ethylene 
oxide, and aired in a fume hood for 24 hours.        
Cell source  
Bone marrow was harvested from the femur and tibia of 6-8 week old New 
Zealand White rabbits (n=3) under Institutional Animal Care and Use Committee of 
the University of Kansas (protocol #175-08).  Bone marrow stromal cells (BMSCs) 
were isolated by density gradient centrifugation (Histopaque; 10771; Sigma; 
Milwaukee, WI) and culture in alpha-MEM (12571; Gibco; Carlsbad, CA), 10% FBS 
(12662; Gibco; Carlsbad, CA), and 1% penicillin/streptomycin (15140; Gibco; 
Carlsbad, CA).  Cells were passaged to P4 (frozen at P2) prior to implantation.   
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Surgical procedure   
Animal experiments were approved by the Institutional Animal Care and Use 
Committee of the University of Kansas Medical Center (protocol #2012-2099).  
Following the induction of stable general anesthesia (ketamine, xylazine, and 
glycopyrrolate administered) and analgesic delivery (buprenorphine), hair was shaved 
from the area around the neck/trachea region of male New Zealand White rabbits (7-8 
lbs) (n=5).  The rabbit was intubated to deliver isoflurane (the defect was created 
above the end of the ET tube, so isoflurane could be reliably delivered).  Intubation 
was assisted with a brochoscope.  Inhaled isoflurane was used to maintain anesthesia.  
Before the procedure, the rabbit was provided with a warmed saline bolus (60mL, 
subcutaneous) to ensure proper hydration and to maintain blood pressure.  The 
surgical area was disinfected with alternate scrubs of surgical scrub (povidone scrub 
or chlorhexidine scrub) and 70% ethanol, and then draped.  Only strict aseptic 
techniques and sterile instruments were used, and the surgeons were wearing sterile 
gown, masks and head covers, as practiced.  
A ventral midline cervical incision was made, including identification and 
division of the strap muscles.  The cervical trachea was accessed.  
Lidocaine/bupivicaine was delivered directly to the defect site or subcutaneously 
prior to surgery to alleviate discomfort associated with defect creation.  An elliptical 
defect was marked out on the wall of the trachea with an approximate size of 0.5 by 
1.5 centimeters (with the long axis oriented along the length of the trachea).  The 
defect was centered approximately 2 centimeters below the cricoid cartilage.  The 
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marked area of tracheal wall was removed with sharp dissection, and the resulting 
hole was patched with a biomaterial scaffold slightly larger than the defect itself in 
order to create an airtight seal (1 by 2.5 cm).   
In the cell seeded group, approximately 25 million cells per rabbit/scaffold 
were prepared with 7-10% of cells labeled with near-infrared fluorescent quantum 
dots (Q25071MP; Life Technologies; Carlsbad, CA) for in vivo cell imaging (data not 
shown) and stored in 37°C media in polypropylene tubes until needed for surgery.  
Prior to seeding, the cell media was removed through centrifugation and cells were 
suspended in 200 uL of PBS.  Once one side of the scaffold was sutured in place, the 
cell slurry was pipetted directly onto the exterior surface of the scaffold and exposed 
side of the scaffold.  Cells were allowed to soak for 5 minutes, excess fluids were 
suctioned from the trachea lumen, and the other edge of the scaffold was sutured in 
place.   
Absorbable polydioxanone suture (size 4-0) was used to suture the scaffold to 
the trachea in all groups.  The wound was then closed in layers using running 
polyglycolic acid absorbable suture in the strap muscle layer and the skin closure 
layer.  After the procedure was finished and the rabbit recovered from anesthesia, 
they were administered meloxicam and returned to their cage once they remained 
sternal.     
Bronchoscopy   
A video-endoscopy system consisting of a bronchoscope (10020ATA; 
Hopkins Telescope, 0°, 2.9 mm, 30 cm; Karl Storz Endoskope; Tuttlingen, Germany) 
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and a video processor coupled to a light source (20045020; TelepackX; Karl Storz 
Endoskope; Tuttlingen, Germany) was used for bronchoscopic evaluation.  The 
degree of reepithelialization over the scaffolded region and appearance of stenotic 
regions of the trachea were evaluated with a bronchoscope at 3, 6, 9, and 12 weeks 
after implantation.  Procedures were done under anesthesia and analgesics were given 
post-procedure. 
Bronchoscopic images were visually assessed and assigned a semi-
quantitative score by the following criteria:  severity of lumen narrowing (none, 
slight, moderate, severe), progression of lumen narrowing (none, slight, moderate, 
severe), direction and type of narrowing (side-to-side, graft collapse, swelling), and 
re-epithelalization of the graft (none, slight, moderate, complete).   
In vivo imaging   
A pre-clinical in vivo fluorescence imaging system (IVIS Spectrum, 
PerkinElmer, Waltham, MA) was used to detect the quantum dot labeled cells.  In 
vivo cell tracking was planned at 3, 6, 9, and 12 weeks post-operation.  Briefly, the 
subjects were anesthetized and positioned in the imaging system to visualize the neck 
region.  The system was set to sweep at excitations of 400, 450, and 550 nm and 
emission collection at 480 and 820 nm.  Fluorescence could not be detected through 
the animal’s skin and muscle (data not shown).  Further cell tracking was not pursued 
during this experiment.  
microCT analysis 
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At 6 or 12 week, tracheas were excised and fixed in 10% neutral buffered 
formalin.  To aid in soft tissue visualization in the microCT analysis, the fixed 
tracheas were soaked in 40% Hexabrix (Mallinckrodt, St. Louis, MO)/60% PBS for 
10 hours.
135
  All tracheas were secured in a vertical position during scanning.  To 
prevent dehydration during scanning, the tracheas were placed in a sealed tube with 
PBS at the bottom.  All scans were performed using a 3D X-ray imaging system 
(Xradia MicroXCT-400, Pleasanton, CA) at 40 kV, 8 W, 2-4 second exposure time, 
0.5x objective magnification.  For high quality images, 1600 projections were 
collected with multi reference images selected at 10 images every 400 frames for a 
total acquisition time of 2.5-5 hours.  After acquisition, the images were manually 
reconstructed using the Xradia software.  The center shift and beam hardening were 
determined.   
Volume quantification 
Following microCT reconstruction, the resulting AmiraMesh files were 
processed in the Avizo Fire software to quantify luminal volume.  A modified pore 
quantification procedure was used.  Briefly, interactive thresholding was used to 
define the void space in the CT image creating a binary image.  The quantification 
command I_Analyze was used to obtain quantitative date (volume, area, length) for 
each void space.  The image was then filtered based on volume, resulting in the 
isolation of the lumen void space from other void space in the image.  Once the 
lumen space was isolated, the volume and length of the 3D image and max/min area 
of the 2D slices were recorded for statistical analysis.  To account for variation in 
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trachea length measured in software, the length was divided by the lumen volume 
creating a normalized volume in cross-sectional units.  
Histological analysis   
Following microCT analysis, the tracheas were soaked in PBS for 24 hrs to 
remove contrast agent and then placed in formalin.  The samples were dehydrated in 
graded ethanol and paraffin embedded.  Transverse sections were taken on a Microm 
HM 355S microtome using a low-profile disposable blade (3052835, Thermo 
Scientific, Waltham, MA) with a sample thickness of 5 μm.  Sections were placed on 
positively charged slides, heated to 60°C for 1 min, and allowed to dry at room 
temperature overnight.  Prior to staining, the slides were heated to 60°C for 45 min.  
After drying, the paraffin was removed from the slides and the tissue was rehydrated 
using CirtiSolv (22143975, Fisher Scientific, Waltham, MA) and a graded series of 
ethanols.    
Hematoxylin and Eosin (H&E) staining for cell nuclei and general tissue 
visualization was performed using the following protocol.  Slides were stained with 
Harris Hematoxlylin (SH30-4D, Fisher Scientific, Waltham, MA) for 3 min, rinsed 
with water, dipped in acid ethanol, rinsed in water, and stained with Eosin Y 
(119830-25g, Sigma-Aldrich, St. Louis, MO) for 30 seconds.  Safranin-O/Fast Green 
staining for GAGs was performed using the following protocol.  Slides were stained 
with Harris Hematoxlylin (SH30-4D, Fisher Scientific, Waltham, MA) for 3 min, 
rinsed with water, dipped in acid ethanol, rinsed with water, stained in Fast Green 
(F7258, Sigma-Aldrich, St. Louis, MO) for 3 min, dipped in 1% acetic acid (537020, 
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Sigma-Aldrich, St. Louis, MO), stained in 0.1% Safranin-O (S8884, Sigma-Aldrich, 
St. Louis, MO) for 10 min, and rinsed with water.  Alcain Blue staining for GAGs 
was performed using the following protocol.  Slides were stained with Alcain Blue 
solution (A3157, Sigma-Aldrich, St. Louis, MO) for 30 min, rinsed in water, stained 
with Nucler Fast Red solution (IW-3021, IHC World, Woodstock, MD), and rinsed 
with water.  Verhoeff-Van Gieson staining was performed using the following 
protocol.  Slides were stained with Verhoeff’s solution (hematoxylin-ferric chloride-
iodine solution) (H9627, 157740, 207772, 221945, Sigma-Aldrich, St. Louis, MO) 
for 1 hour, rinsed with water, dipped in 2% Ferric Chloride (157740, Sigma-Aldrich, 
St. Louis, MO) for 2 min, rinsed with water, dipped in 5% sodium thiosulfate (S7026, 
Sigma-Aldrich, St. Louis, MO) for 1 min, rinsed in water, and stained in Van 
Gieson’s solution (1% aqueous acid fuschin in picric acid) (F8129, Sigma-Aldrich, 
St. Louis, MO; 80456, Fluka, Buchs, Switzerland) for 5 min.  Sudan Black B for 
residual polymer was performed according to manufacturer’s instructions (IW-3021, 
IHC World, Woodstock, MD).   
All sections were then dehydrated in graded alcohol and then cleared in 
Citrisolv and mounted, with the exception of Sudan Black where the sections 
remained hydrated and were mounted with aqueous mounting medium (E01-15, IHC 
World, Woodstock, MD).  Photomicrographs were taken of representative sections.   
Histological scoring   
The histological sections were scored blind by a pathologist (RG).  The 
scoring system was developed to evaluate inflammation, vascularization, 
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epithelialization, cartilage formation, and residual polymer.  The location of 
inflammation was determined by the spatial organization of inflammatory cells/tissue 
(diffuse or on outer surface of scaffold) and severity of inflammation was determined 
by the thickness of the “cap” like tissue on the exterior surface of the scaffold, none 
(0), thin layer (1), moderate layer (2), and thick layer (3).  Immune cells types were 
differentiated into multi-nucleated giant cells (MNG cells), mononuclear cells 
(macrophages, lymphocytes, plasma cells), heterophils (rabbit analog of neutrophils) 
108
, and eosinophils and quantity of cells observed were categorized into none (0), 
mild (1), moderate (2), severe (3), and extreme (4).  To determine vasculature, four 
representative fields of inflamed tissue were examined at 40x and vessel cross 
sections containing erythrocytes were counted.   
Epithelialization was analyzed by simply categorizing it into two groups—
presence or absence of epithelium (yes or no).  The epithelial character were 
described and categorized into pseudostratified columnar, simple cuboidal, stratified 
cuboidal, simple columnar, squamous, and ulcer formation.  Subepithelial character 
was described as fibrous, vascular, inflamed, or a combination.  Cartilage formation 
was assessed by detecting new or immature cartilage and by assessing collagen 
staining (Verhoeff-Van Gieson) and collagen location.  The presence of obvious 
fibroblasts and their location were also noted.  The amount of polymer present was 
ranked from no polymer (0), 25% (1), 50% (2), 75% (3), and 100% of polymer 
present (4).     
Statistical analysis 
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Using one-way ANOVA and Tukey’s posthoc analysis, the bronchoscopy 
rating, lumen volume, and histological scoring were determined to be significant if 
p<0.05.    
 
RESULTS 
Mortality   
The implantation of the scaffolds was straightforward, with the scaffolds 
being easily cut into the desired elliptical shape in the operating room and sutured 
into the induced defect (Figure 5.2).  Throughout the 6 or 12 weeks of the study, a 
majority (73%) of the rabbits did not display any signs of distress.  In the event of an 
adverse reaction (i.e., labored breathing, coughing, weight loss, stridor, death), the 
rabbit underwent bronchoscopic evaluation, vital sign monitoring, and more frequent 
monitoring.  If the animal’s condition was rapidly declining and no intervention 
methods were available, euthanasia was determined to be the best course of action.  
Adverse events occurred in 27% of the total study population, with a breakdown of 
10% occurring in the scaffold only group (3% of 6 wk and 7% of 12 wk), 13% 
occurring in the TGF-β3 group (6.5% of 6 wk and 6.5% of 12 week), and 3% 
occurring in the BMSC group (3% of 6 wk and 0% of 12 wk).  13% fatality (4 out of 
30 subjects) occurred during the first 6 week time point and 27% fatality (4 out of 15 
subjects) occurred during the final 6 weeks (Figure 5.3).   
Bronchoscopy   
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The purpose of the bronchoscopic analysis was to reveal the real-time 
morphology of the airway through the course of the study (Figure 5.4).  Images were 
compared side-by-side and assigned a stenosis severity, progression of stenosis, re-
epithelization rating, and type of narrowing (Figure 5.5).   
 Severity of stenosis was assessed on a scale from none (1), slight (2), 
moderate (3), to severe (4).  We observed that the later time point subjects (12 week) 
had a higher severity rating than the earlier time point (6 week).  Additionally, the 
adverse events all exhibited the most severe level of stenosis, although no statistical 
analysis could be done due to group size limitations. 
 Of the cases exhibiting slight to severe stenosis, the progression of the 
stenosis over time was evaluated on a scale from none (0), slight (1), moderate (2), to 
severe (4).  Similar to the stenosis severity rating, we observed that the later time 
point subjects (12 week) exhibited a more extreme progression of stenosis as 
compared to the earlier time point (6 week).  Between the groups, the week 12 and 
adverse event cases in the TGF-β3 group had a more rapid progression of stenosis as 
compared to the other groups, although statistical analysis could not be done due to 
group size limitations.    
 Re-epithelialization was assessed on a scale from none (0), slight (1), to 
moderate (2).  All subjects exhibited some degree of epithelialization over the implant 
area.  The degree of epithelialization seemed to decline over time in the TGF-β3 
subjects, where a moderate degree of epithelialization was observed at week 6 and a 
slight degree of epithelialization was observed at week 12.  Between the groups, the 
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BMSC cases displayed more epithelialization than the Scaffold-only cases.  The fatal 
cases appeared to have a lesser degree of epithelialization, all scoring at slight 
epithelialization. 
The types of stenosis (of the stenotic cases) were categorized into side-to-side 
narrowing, in-folding of one of the tracheal walls, and scaffold displacement into the 
airway.  It is important to note that no granulation tissue (obvious protrusion of 
granular tissue) was observing on the lumen surface of the implants, indicating that 
inflammatory tissue overgrowth occluding the airway was not the type of stenosis 
observed.  A large majority of the subjects exhibited a side-to-side narrowing (84% of 
total subjects with stenosis), with fewer subjects exhibiting one-wall in-folding (8% 
of total subjects with stenosis) and scaffold obstructing airway (8% of total subjects 
with stenosis).  The two cases of scaffold obstruction occurred in the Scaffold-only 
group and the two cases of one-wall in-folding occurred in the Scaffold-only and 
BMSC group.    
In summary, bronchoscopy data indicated that stenosis progressed over time, 
fatality is linked to stenosis, and epithelium was present in all groups.  
Gross morphological observations 
At the time of harvest, the gross morphological observations of the tracheas 
revealed the presence of polymer and tissue growth around the scaffold, for all 
groups.  Some narrowing in the scaffolded region was observed, in most cases.  
microCT and volume quantification 
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Visual inspection of the microCT scans revealed that all groups have some 
degree of stenosis as compared to a native, unaltered trachea.  Analysis with 
specialized imaging software provided quantitative lumen volume data (Figure 5.6).  
Volume quantification indicated that the Scaffold-only and TGF-β3 groups 
performed similarly to the native trachea at both 6 and 12 weeks.  In contrast, the 
adverse events (fatalities) in the Scaffold-only and TGF-β3 group have a reduced 
lumen area (p<0.05) as compared to a native trachea.  The BMSC group at week 6 
and 12 had a lesser lumen area (p<0.05) as compared to the native trachea (Figure 
5.7).   
Statistical comparison within groups and between groups was performed.  
Within the Scaffold-only group, the week 12 subjects had a lumen area that was 
significantly larger than the adverse events.  For this group, the normalized lumen 
area that is indicative of fatality was approximately 0.19 ± 0.02 cm
2
.  Among groups, 
the Scaffold only-week 12 scaffolds had significantly larger lumen than the BMSC-
week 12 scaffolds (p<0.05).  
In addition, the 2-D CT slice data was analyzed (data not shown) and the 
location (cranial, middle, caudal) of the narrowest region of the trachea were 
summarized.  The point of greatest stenosis occurred exclusively at the midpoint of 
the implant (data not shown).  
In summary, CT quantification data indicated that the Scaffold only group had 
larger tracheal volumes, and thus less stenosis, than the BMSC group.  The BMSC 
group and adverse events in all groups has significantly smaller airways than the 
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normal trachea.  And finally, adverse event subjects had smaller lumen area, 
indicating there could be a threshold associated with fatality.  
Histology 
Macroscopic assessment of immune cells involved evaluating thickness 
(linked to severity) and location of the immune cell containing region.  Immune cells 
were mainly located on the outer layer of the scaffold, forming a “cap” over the 
scaffold (Figure 5.8).  Diffuse distribution of immune cells was only observed in two 
subjects (scaffold-only and TGF- β3 adverse events).  Although no statistically 
significant difference could be determined for inflammation severity, a trend of 
increasing severity over time and in the adverse events was observed (Figure 5.10).  
BMSC seeded scaffolds at week 12 had more severe inflammation (a thicker layer of 
inflammatory tissue) than the scaffold-only group at week 6 (p<0.05).   
 Microscopic assessment of immune cell types showed that MNG cells are 
severely present in all groups, except for a few adverse event cases (Figure 5.10).  
Mononuclear cells are also moderately to severely present in all groups.  Heterophils 
were moderately present.  Eosinophils were not present except for a single case in the 
scaffold-only group and a single case in the BMSC group (Figure 5.9). 
 The quantification of blood vessels shows that the TGF-β3, week 6 group had 
a significantly higher quantity of vasculature than other groups and at other time 
points (and adverse events) within the TGF-β3 group (p<0.05) (Figure 5.10).  It 
appears that the TGF-β3 treatment increases vasculature at early time points but the 
vasculature declines at later time points.  Adverse events in the scaffold-only group 
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and TGF-β3 group had more vasculature than at non-fatal cases within their 
respective groups (p<0.05).   
Epithelium assessment revealed that all scaffolds had epithelium, except for 5 
adverse event cases.  Of the case with epithelium, a variety of epithelium was present.  
Epithelium was ciliated to some degree in all subjects.  Pseudostratified columnar 
epithelium was the most common epithelium, with 21 subjects exhibiting this 
morphology (Figure 5.9).  Of the 21 cases, 15 subjects only possessing this 
epithelium and 6 of those cases had a combination of other types of epithelium—
cuboidal, simple cuboidal, stratified cuboidal, and simple columnar.  A majority of 
the pure pseudostratified columnar cases were from the BMSC group (7 cases) and 
the week 12 cases (9 cases).  This is suggestive that cell-seeding and time encourage 
normal epithelial formation.  The simpler epithelium (e.g., simple columnar, cuboidal, 
and squamous types) was observed in 5 cases and those cases were in different 
treatment groups but all at 6 weeks.  This could indicate that more complex 
epithelium takes time to migrate and develop on the scaffold lumen 
34
.  Ulcers were 
observed in the adverse events subjects (4 cases), indicating that granulation tissue 
was present in the airway (that could not be determined with bronchoscopy).   
 The subepithelium was assessed for its vascular and fibrous nature (Figure 
5.9).  Inflammation was also noted.  A large majority of subjects had a fibrous 
character (10 purely fibrous and 16 in combinations with vascular or inflamed tissue).  
BMSC seeded scaffolds made up the majority of fibrovascular subepithelium (6 of 9 
cases), suggesting cells could positively influence a normal subepithelial appearance.  
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Subepithelial vasculature was observed in 13 cases and inflammation was observed in 
7 cases.  The scaffold-only subjects did not have any occurrence of inflamed 
subepithelium, while adverse event cases usually had inflamed subepithelium (6 of 8 
cases).       
 Regions of immature cartilage formation were observed at defect edges and 
over the defect (in a couple cases) (Figure 5.9).  Scaffold-only subjects had 3 cases of 
immature cartilage formation, with 2 cases at 6 weeks and 1 case at 12 weeks.  TGF-
β3 subjects also had 3 cases, with 2 occurring at 12 weeks and 1 occurring in an 
adverse event case.  The cell seeded group had 6 instances of new cartilage formation, 
occurring mainly at 12 weeks (4 cases).   
 Assessment of obvious fibroblast appearance and location reveal that 
fibroblasts were observed in all subjects, usually oriented in a layer around the 
scaffold, between scaffold layers, and in the subepithelium (Figure 5.9).  Unique 
fibrous, connective tissue was observed inside the scaffold in the 6 week BMSC cases 
located inside the scaffold, indicating that the BMSCs could have formed or recruited 
cells to form this tissue (Figure 5.9).  Amount of collagen and location of the 
deposited collagen were assessed.  Collagen was moderately present, with no 
particular difference between groups, and was located in similar regions as the 
fibroblasts (i.e., around the scaffold) (Figure 5.10). 
 Though no statistically significant difference could be gathered from this data, 
there is a decreasing amount of polymer remaining over time and the BMSC group 
had fewer polymer present as compared to the other groups (Figure 5.10).   
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 In summary, the outer surface of the scaffold was covered by a layer of 
inflammatory cells, with a thicker layer of these cells occurring in the BMSC group 
than the Scaffold-only group.  The immune cells present (as can be determined with 
H&E staining) were MNG cells, mononuclear cells, and heterophils.  Degree of 
vascularization was higher in the TGF-B3 group (when compared to the other 
groups), but the vasculature diminished by 12 weeks.  Normal epithelium 
(pseudostratified columnar) presented more often in the BMSC groups and at later 
time points.  Fibrovascular subepithelium occurred more often in the BMSC groups, 
while the Scaffold-only group had no incidences of inflamed subepithelium.  
Immature cartilage was observed across all groups, but with a higher occurrence in 
the BMSC group.  Fibroblasts and collagen were present in all subjects, mainly 
organizing around the scaffolds and within the scaffold.  Normal connective 
fibroblastic tissue was observed inside the BMSC group scaffolds.          
 
DISCUSSION 
We observed that severe stenosis did not always result in fatality.  Of the 
bronchoscopy images scored as severe, approximately half were fatal.  Severe 
stenosis appears to be necessary for fatality, but does not necessarily lead to fatality.  
The animal model for the current study, the rabbit, was chosen because the trachea is 
similar in size to a pediatric trachea.  We observed that the predominant type of 
stenosis was tracheal wall deformation and migration of native trachea wall into the 
laryngofissure, not graft dislodgement occluding the airway.  This wall deformation 
 
97 
could be due to 1) the scaffold weakness and inability for construct to adequately 
support the surrounding tissue, 2) inflammatory response, or 3) the innate fragility of 
the rabbit trachea wall that is compounded by the defect creation.  An understanding 
for the reason for fatality is needed.   
After seeing this variable response to stenosis and delicate nature of the rabbit 
trachea, this leads us to reassess our animal model.  There is no agreed upon animal 
model for tracheal research, and the animals have ranged from nude mice to pigs.
118
  
Recently it was determined that the rabbit trachea has a reduced capacity to resist 
compressive or tensile forces as compared to a sheep or human trachea.
42
  The rabbit 
was an adequate model for small animal work, but future in vivo work could include a 
more mechanically robust trachea (e.g., sheep or pig).  
The CT lumen quantification data suggested that the TGF-β3 group (and the 
Scaffold Only group) has a significant similar lumen area to the native trachea.  Also 
the scaffold-only group had a statistically significant improved lumen area as 
compared to the BMSC-seeded group.  The native trachea-like performance of the 
scaffold-only group and TGF-β3 group indicates that an acellular approach is a viable 
option for trachea defect repair.  Reasons that the BMSC group had a reduced 
performance could be linked to the more severe inflammatory response present 
around those scaffolds. 
Acute inflammatory cells (heterophils) and chronic inflammatory cells 
(mononuclear, MNG cells) were present in all cases 
69
.  As tissue was collected at 
later time points (6 and 12 weeks) the later stages of the inflammation response were 
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captured with histology—small population of heterophils and larger population of 
mononuclear and MNG cells.  In the fatality cases, the inverse was observed with 
higher populations of neutrophils and lower populations of MNG cells.  The inverse 
cell profile in fatal and nonfatal cases indicates that fatal cases had an acute 
inflammatory reaction, which could be related to 1) the earlier collection of tissue or 
2) the host cells could not transition to chronic inflammation with potential for 
healing.  No clear trend in cell types was observed between groups, except that the 
inflammation severity (thickness of inflammatory cell layer) was higher in the BMSC 
group than other groups.  Although an immune response severity occurred in the 
BMSC group, survival was the highest in this group.  Thickness of accumulated 
immune cells over the implant may not be linked to survival, although this indicates a 
heightened immune response.   
 Immature cartilage was observed in all groups, but more often in the BMSC 
group.  This could indicate that the cartilage is either an artifact of the histology 
section or the BMSCs contributed to cartilage formation.
101
  Vasculature was 
observed in all subjects, and the TGF-β3 treatment increased vasculature at early time 
points but the vasculature declines at later time points, which is expected as TGF-B3 
induces angiogenesis 
94
.  Angiogenesis occurs in granulation tissue and the normal 
healing process.   
Less residual polymer was present in the BMSC group, indicating that the 
addition of cells could speed degradation, which could be potentially related to 
increase phagocytosis of polymer material by immune cells.  The amount of 
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inflammatory tissue was increased in the BMSC group.  Although no statistically 
significant difference was observed in this observation, so trends are not conclusive.   
The difference between the bronchoscopy rating and the CT lumen 
quantification, specifically in regards to the TGF-β3 loaded scaffolds, could occur 
because 1) of the subjective nature of the bronchoscopy rating, 2) the lumen 
quantification’s ability to account for the length of stenosis which can be difficult to 
determine from the 2D fixed view of the bronchoscopic images, and 3) tissue 
distortion occurring during the excision and fixation processes.  Furthemore, the 
airway is dynamic, so the lumen can change shape and size based on inspiration and 
expiration.  These static testing methods, like microCT, only evaluate the trachea 
dimensions at one morphology.  If live CT methods are employed in the future, four-
dimensional dynamic volume multidetector computed tomography (4D-CT) could be 
used to account for variation in airway diameter. 
The reason for fatality the large study as compared to the pilot studies needs to 
be investigated.  The possible reasons could be:  1) the low statistical power in the 
pilot studies undermining the true effect of our scaffolds or 2) an experimental 
variation between the pilot studies and this large scale study.  The latter seems more 
likely as some degree of adverse reaction would have occurred in the pilot studies that 
would have been comparable to the reactions observed in the current study.  The 
variation between the pilot and large experiments are: 1) change in electrospinning 
solvent from dichloromethane (DCM) to HFIP, 2) variable electrospinning 
parameters that affect scaffold thickness or morphology, 3) animal size changed from 
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8-9 lb in pilot study to 7-8 lb animals in large study, or 4) variation in surgical 
technique.  The most likely from this list could be the solvent change, although any 
residual solvent should be removed as the scaffolds are lyophilized and fumed for 2 
days, or the difference in animal size.  As mentioned previously, the rabbit trachea 
walls have reduce mechanical properties and thus a smaller animal could have more 
fragile walls than a larger animal.  Cytotoxicity testing should be done to determine 
solvent effects. 
Future directions and improvements for this work include measuring the 
stenosis during bronchoscopy (with a balloon or other method) so we should calculate 
a percent reduction in area of a finite segment of the tracheal cylinder encompassing 
the stenosis site.  Additionally, an estimate of the added airway resistance over what 
the normal resistance would have been without the narrowing.  While these two 
approaches would be much more difficult, they would add more data obtained from 
bronchoscopy.  Further histological and immunohistological staining to clarify the 
specific immune cells types, for example, determining the type of macrophage which 
could illuminate the direction of healing 
13
.  In addition, a different surgical technique 
could be used to induce defects (e.g., laser or brush stenosis) , to implant scaffold (in 
line with trachea rather than overlap), and to revascularize (pedicle flap over implant).  
Most importantly, the scaffold could be redesigned to anchor the tracheal walls and 
prevent any wall migration into the airway.  Success has been seen in extra-tracheal 
tracheal splints.
145
  We are designing the next generation of implant that will 
incorporate extra external support rings that would extend from the patch and could 
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be additional suture points to anchor the tracheal wall to the scaffold.  A tubular 
scaffold is also in development that could expand this research from small, patch type 
defects to larger segmental defects. 
We have illustrated that our scaffolds maintain functional airways in a 
majority of cases.  While the cell-seeded group had an improved survival rate, the 
acellular group had a higher occurrence of more patent airways and the BMSC group 
has reduced areas.  The BMSC group had a more severe accumulation of immune 
cells over the graft, while also exhibiting more normal epithelium, subepithelium and 
cartilage formation.    This leads us to conclude that a simple, acellular scaffold is a 
viable option for tracheal tissue engineering, with the intraoperative addition of cells 
being an optional variation to the scaffolds.  In conjunction with work to investigate 
reasons for tracheal obstruction disease pathology and development preventative 
treatment, our approach could treat patients that have already developed narrowing.  
Our fibrous bilayer scaffolds provide a clinically-relevant, off-the-shelf approach to 
tracheal defect repair.           
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CHAPTER 6:  Conclusion 
 
After the decision to apply electrospun materials to tracheal tissue 
engineering, this research has established the fabrication methods required to 
manufacture tracheal scaffolds, characterized the morphological and mechanical 
properties of these scaffolds under in vitro degradation, and demonstrated 
functionality in an in vivo model.  The series of in vivo studies refined the scaffold 
design and surgical technique.  Overall, this work has characterized the use of 
reinforced, graded, fibrous materials for tracheal defect repair.         
  The in vitro characterization revealed that the short-term degradation of the 
fibrous PLGA component increased porosity, while the fibrous PCL component 
reliably held sutures and contributed to recovery from radial compression.  The 
addition of the 3-D printed PCL ring largely improved mechanical properties under 
tension and radial compression.  When compared to desired outcome measures, the 
gradient scaffolds with ring supports had superior properties compared to other 
variations of the scaffold.  The limits of this scaffold design were the decreased 
porosity due to the non-porous PCL ring and the larger fiber diameters due to the 
PLGA component.  Future work should investigate increasing porosity of the ring 
with 3-D printing and solving the sterilization deformed fibers.       
The in vivo characterization showed that the scaffolds can maintain a 
functional airway in a patch-defect, although the large-scale study has more adverse 
outcomes than the previous two pilot studies.  More data was gathered in the full-
scale study from bronchoscopy, microCT, and histology to evaluate the scaffolds.  I 
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observed that the scaffold-only subjects exhibited larger tracheal lumen volumes and 
a lower inflammatory response, the TGF-β3 group also had larger tracheal lumen 
volumes and had improved vasculature, and the cell-seeded group had less fatality 
and a promising immature connective tissue growth inside the scaffold.  Overall, I 
observed that cells infiltrated into the scaffolds and replaced the regions of degraded 
PLGA.  The cell types present were immune type cells (indicating an inflammatory 
process), fibroblasts, and epithelium.  The addition of growth factors demonstrated an 
increase in collagen II (second pilot study) and an increase in vascularity of the tissue 
(full scale study).  The addition of cells produced a slightly higher inflammatory 
response while producing normal connective tissue in and around the scaffold.    A 
redesign of the scaffolds is needed to improve cell-seeding methods, growth factor 
delivery, and tracheal reinforcing techniques (i.e., surgical technique and external 
tracheal splint).  Specfic redesign include extending PCL rings beyond fibrous portion 
to create a cage around the trachea to act as an external splint and suture anchor 
points (e.g., cage or spider-type design).  The results of this study proved that a 
reinforcing component (e.g., ring) is required for improved mechanical performance 
and that the graded fibrous component provides desirable degradation properties, 
porosity, and microenvironment.  Therefore, I have demonstrated that a scaffold-only 
approach can maintain the airway, but the addition of growth factors and cells could 
improve upon the scaffold-only approach.   
After in-depth analyses of our scaffold system, areas that require further study 
include determining cytotoxicity of scaffolds to determine if that could be the cause 
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of fatality in the in vivo study.  In the electrospinning field, there is a call for less use 
of organic solvent (e.g., melt electrospinning), although these solvents contribute to 
the easy creation of submicron, uniform fibers.  Characterization of residual solvent 
(e.g., HPLC or mass spectroscopy) and a more thorough protocol for solvent removal 
could also aid in reducing potential cytotoxity.   
Other considerations should be the scale up of the scaffold fabrication process.  
Developing the equipment to make uniform, repeatable scaffolds with less human 
interaction (e.g., manual addition of PCL rings) is required for marketing and use of 
the scaffolds.    
Characterization of the encapsulated TGF-β3 is needed.  Preliminary work 
quantified growth factor release and bioactivity, although technical and time 
limitations cut that work short.  In vivo work demonstrated that TGF-β3 had an effect 
on collagen II and vascularization of the implant, indicating that the TGF-β3 was 
bioactive.  Further work should be done to refine growth factor release and to identify 
other beneficial proteins that could reduce severe inflammation and regenerate the 
complex tracheal tissue (i.e., cartilage, epithelium, glandular-tissue, muscle, 
vasculature).     
My work focused on regenerating the structural component of the trachea, the 
cartilage.  In vivo, fibroblasts and collagen were present in and around the scaffold, 
but normal connective tissue was observed in the cell-seeded group.  The presence of 
normal connective tissue, unique from the fibroblasts that surround the scaffold, 
indicates that the BMSCs were surviving and populating the implant.  Future work 
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with growth factors and cells should include utilizing no animal products (e.g., BSA 
carrier for TGF-β3), autologous cells (e.g., bone marrow aspirate or alternative stem 
cell source), the combination of growth factor and cells for further differentiation of 
the stem cells, and in vitro seeding of the implant prior to implantation.   
Future directions for scaffold design would be to investigate other polymer 
types (e.g., poly(L-lactide-co-caprolactone)) and biological materials (e.g.,. collagen, 
decellularized tissue).  Understanding the immune response to the implant is crucial 
for implant acceptance and incorporation into the host.  Further immune 
characterization is needed to determine inflammatory cell types (using cell surface 
marker), which could indicate the type of inflammatory process that is occurring.  
Innovative research in immunomodulatory tissue engineering approaches could be 
applied to the scaffolds to control the host’s immune response.  One such approach 
could be incorporative antiproliferatives (e.g., rapamycin or paclitaxel) into the 
electrospun fibers to reduce the inflammatory response.
24
  The antiproliferatives 
prevent smooth muscle cell growth during the first 2-3 weeks after implantation, 
when risk of inflammation is greatest. 
 Developing the in vitro and in vivo models for tracheal implants is crucial for 
predicting response in humans.  Intricate in vitro cell culture system could be used to 
mimic the airway conditions.  Once such model could be an air-liquid interface 
system, where the implant could be exposed to liquid (e.g., cell culture medium) on 
one side and air on the other.  For the in vivo model, new defect creation methods 
should be deployed to create a stenosis model closer to the human occurrence of 
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stenosis (e.g., laser or brush irritation of the tracheal lumen).  Alternative animal 
models could also be used.  The rabbit is an ideal small animal model, but further 
work should be done in larger animal models such as sheep and pigs.  Another avenue 
for in vivo research could be on client-owned animals with naturally occurring 
tracheal stenosis.
8, 36, 63
  Dogs are one such case, where the tracheal cartilage ages and 
degenerates to a point that it collapses (late stage tracheomalacia).  This could be a 
potential new market for tracheal implants.   
The typical strategy for evaluating medical products is to test in vitro (with 
cells), in vivo (with a progression from small to larger animals), and finally clinical 
testing in humans.  Pilot in vivo studies can be executed first to overstep the 
inadequacies of in vitro testing and to determine if the product functions in its desire 
application (orthotopic).  This pilot study approach is valid for speeding product 
development by eliminating products/designs that fail in the pilot study stage, with 
criteria for failure including adverse events, death, or lesser performance to current 
medical treatment.  My pilot studies were successful but when transitioned to a full-
scale in vivo study, the fatalities caused room for concern.  In hindsight, before 
attempting a large-scale in vivo study, I believe that it is wise to check in vitro 
performance before investing in expensive and time consuming full-scale in vivo 
testing.  Valuable information can be gathered from in vitro testing following a pilot 
study, such as cytotoxicity (ISO 10993-5 and FDA blue book memorandum #G95-1), 
cell infiltration, differentiation, etc.  In the case of my studies, I believe that the 
change in electrospinning solvent and decreased rabbit size from pilot to full-scale 
 
107 
study and may be linked to the increased fatalities.  In the case of the solvent change, 
in vitro testing could have illuminated the cytotoxicity.          
Another observation made from comparing our group’s knee research to the 
trachea research is the dramatically different response to scaffolds in vivo.  The knee 
studies have not resulted in fatality, while the trachea models have been less 
successful. The implantation of tracheal scaffolds is a risky surgery, with a more 
acute response to implantation (e.g., a compromised airway).  It has been reported 
that an unfavorable microenvironment may exist in the neck (i.e., vascularized 
environment with different immunological properties than the knee).
128
  Thus scaffold 
development for the trachea should have special consideration.   
Translating tracheal tissue engineering into the clinic will require thorough 
characterization and development of the tracheal constructs, in vitro and in vivo.  
Studies like those presented in this thesis refine scaffold design to meet the clinical 
need.  My approach of using fibrous degradable synthetic materials overcomes the 
limited availability, specialized preparation, and storage of donor tissues, and the 
limited regenerative capacity of non-degradable materials.  Graded, fibrous scaffolds 
with reinforcing rings can be an alternative to the current standard of care.  Although 
further research and redesign of the scaffold is warranted, these materials can be 
beneficially incorporated with growth factors and cells.  The application of 
electrospun materials to tracheal defect repair has been taken from idea to practice in 
this thesis and has established a platform for further research and development, with 
the potential for translation into clinical use.   
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APPENDIX A:  Figures 
 
Chapter 3:  Figures 3.1-3.10 
Chapter 4:  Figures 4.1-4.16 
Chapter 5:  Figures 5.1-5.10 
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3. Chapter 3 
 
Figure 3.1: In vitro characterization of tracheal scaffolds.   
Seven different types of scaffolds were tested—1) Polycaprolactone (PCL)-only, 2) 
poly(lactic-co-glycolic acid) (PLGA)-only, 3) Co-spun, 4) Blend, 5) Bilayer, 6) 
Gradient, 7) Gradient+ rings.  Scaffolds were aged for 12 weeks and the scaffold 
morphology, degradation, porosity, and mechanical properties were evaluated.  
[SEM—scanning electron microscopy, SEC—size exclusion chromatography]   
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Figure 3.2: Gross morphology of aged scaffolds. 
Scaffolds from all groups (except for Gradient+Rings) are presented as an anterior 
view of disk scaffolds.  Gradient+Rings is a cross-section view of tubular scaffolds.  
The PLGA component degraded after 2 weeks in the PLGA-only group. The PCL 
component maintained the scaffold shape in all other groups. 
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Figure 3.3: SEM images of cross-sections and aged scaffolds.  
The PCL fibers are more uniform and the PLGA fibers are flattened and larger.  In 
the cross-section images, arrows indicate the interface between layers and the scale 
bar is 200 microns.  20 microns represents columns 2-4, which are magnified images 
of the different treatment groups.  The scaffolds with two layers have images for both 
layers. 
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Figure 3.4: Mass loss (%) of aged scaffolds. 
All PLGA containing scaffolds exhibited significant mass loss, while the PCL-only 
group did not lose mass.  Data represents averages and error bars represent one 
standard deviation (n=3). 
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Figure 3.5: Weight-average molecular weight (Mw) for all retained scaffolds. 
MALS and RI data followed similar trends, with a decrease in molecular weight of 
PLGA containing groups up to 6 weeks.  PCL and PLGA chromatography peaks were 
differentiated by retention time, with slight overlap at 0 weeks.  Data represents 
averages and error bars represent one standard deviation (n=3). 
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Figure 3.6: Porosity (%) of scaffolds. 
Scaffolds increased in porosity over time, with the PLGA-only group being the least 
porous ($ denotes significantly smaller porosity than all other groups, p<0.05).  The 
Gradient+Rings group decreased in porosity with time, due to the remaining PCL 
rings (@ denotes significant porosity decrease from all other groups, p<0.05).  PCL-
only scaffolds were less porous than the Gradient scaffolds at week 12 (denoted by #, 
p<0.05).  Data represents averages and error bars represent one standard deviation 
(n=3). 
 
 
 
129 
 
Figure 3.7: Tensile properties of aged scaffolds. 
Gradient+Rings had superior Young’s and equilibrium modulus as compared to all 
other groups (denoted by #, p<0.05).  PCL and Bilayer scaffolds at week 0 performed 
similarly to the Gradient+Rings scaffolds at week 0 (denoted by *).  Data represents 
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averages and error bars represent one standard deviation (n=3). 
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Figure 3.8: Diameter change during burst pressure testing. 
As scaffold degraded, the diameters deformed (mm) more in response to the catheter 
balloon inflation.  At week 0, scaffolds resisted deformation, except for PLGA-only.  
No statistically significant differences were present.  Data represents averages and 
error bars represent one standard deviation (n=3). 
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Figure 3.9: Suture Retention Strength (SRS) of scaffolds. 
Data represents averages and error bars represent one standard deviation (n=5).  
Circumferential and axial testing simulated suture pull-out in the circumferential 
and axial directions when implanted in a trachea.   
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In the circumferential direction: SRS decreased from 0 to week 3, week 6, and 
week 12 (denoted by ^, p<0.05), Gradient SRS also had degradation dependent 
decline in SRS from week 0 to week 3 (denoted by ^, p<0.05), PCL Only, week 
12 SRS were higher than Co-spun and Blend scaffolds at week 12 (denoted by $, 
p<0.05), PLGA Only, week 0 SRS were lower than all groups at week 0 (denoted 
by *, p<0.05), Blend, week 3 SRS were lower than PCL Only, Bilayer, and 
Gradient+Rings at week 3 (denoted by +, p<0.05), Blend, week 6 SRS were 
lower than PCL Only, Bilayer, Gradient, and Gradient+Rings at week 6 (denoted 
by ?, p<0.05), and Gradient+Rings, week 12 SRS were higher than Co-spun at 
week 12 (denoted by =, p<0.05).  
 
In the axial direction: Blend and Gradient scaffolds were affected by degradation 
with the SRS decreasing over time (Blend, week 0-week 6 and week 0- week 12; 
Gradient, week 0-week 3) (denoted by ^, p<0.05), PCL Only and 
Gradient+Rings, week 12 had greater SRS than Co-spun and Blend at week 12 
(denoted by $ and %, p<0.05), and  PLGA Only, week 0 SRS were lower than 
Blend, Bilayer, and Gradient at week 0 (denoted by #, p<0.05).   
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Figure 3.10: Tube flattening and recovery. 
Data represents averages and error bars represent one standard deviation (n=5). The 
load required to flatten the scaffolds followed an overwhelming trend, where 
 
135 
Gradient+Rings scaffolds outperformed all other groups at corresponding time points 
(denoted by #, p<0.05).  The recovery of scaffolds after flattening revealed that Co-
spun and Blend scaffolds at 3, 6, and 12 weeks remained in a flatter state (or 
recovered less) than PCL Only, Bilayer, Gradient, and Gradient+Rings at the 
corresponding time points (denoted by *, p<0.05).  Gradient+Rings scaffolds at week 
0 recovered better than Co-spun and Blend at week 0 (denoted by = &, p<0.05).  PCL 
Only, week 0 scaffolds recovered less than at week 6 (denoted by !, p<0.05).  The 
reason for this may be due to measurement error or variability in scaffold properties 
or geometry.  Co-spun, week 0 scaffolds recovered better than week 6 (denoted by #, 
p<0.05).  Blend, week 0 scaffolds recovered better than week 6 and week 12 (denoted 
by #, p<0.05).        
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Figure 4.1: Pilot studies experimental design. 
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Figure 4.2:  Creation of patch-type scaffold. 
Demonstrating how the elliptical patch (1 cm by 2.5 cm) was cut from the cylindrical 
scaffold.  A sheet of biomaterial is removed from the electrospinning 
collecting rod and a predefined elliptical shape was cut out with a scalpel. 
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Figure 4.3: Demonstrating that scaffolds are suturable. 
Demonstrating that a suture can easily be run through the scaffold, which is important 
for practical ease of use for surgeons. 
 
 
Figure 4.4: Gross morphological images of tracheas with scaffolds. 
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Gross appearance of the implant after 7 weeks, prior to excision of the trachea.  
Excised trachea after preliminary study (ruler = cm, arrow indicates PCL scaffold). 
 
Figure 4.5: CT scans from the first pilot study. 
Transverse plane of CT scan revealed that the airway was not blocked (image 
representative of both rabbits). The 3-D reconstruction suggests a change in tissue 
density in the region were the scaffold was implanted, suggesting a lack of cartilage 
arch formation (arrow indicates implant). 
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Figure 4.6: Histology images from first pilot study. 
Figure 3.6:  The lumen (L) was covered with a layer of normal ciliated respiratory 
epithelium (arrows) (H&E). Scale bar represents 0.1 mm. Multinucleated giant cell 
found in the scaffold with biomaterial fibers observed inside the cell mass (arrow) 
(H&E).  Scale bar represents 10 µm. Overlap (O) of scaffold (S) over native cartilage 
(N); notice difference in staining intensity between native cartilage and scaffold 
(H&E).  Scale bar represents 0.5 mm. 
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Figure 4.7: Gross morphology of excised trachea from the second pilot study. 
The trachea was collected at 6 weeks.  The circled region represents the scaffold, 
which is covered with tissue and residual polymer is visible.   
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Figure 4.8: Transverse microCT slices from the second pilot study. 
 
The scaffold is located at the 6 o’clock region of the trachea circumference.  The 
lumen volume was measured and percent stenosis was calculated.  
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Figure 4.9: Tracheal stenosis (%) from the second pilot study. 
Percent stenosis was calculated by obtaining diameter measurements form CT scans 
and comparing implanted tracheas to normal tracheas.  Subjects exhibited a 30-45% 
stenosed airway.  No statistically significant difference determined due to sample 
size.  Data represents averages and error bars represent one standard deviation (n=2). 
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Figure 4.10: Histological images (H&E and Safranin O) of tracheas from the second 
pilot study. 
Cells infiltrated into the scaffold (S) and areas of Safranin O staining around the outer 
surface of the Gradient w/Growth Factors scaffold were indicative of proteoglycans.  
Native cartilage (C) is represented in the images.   
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Figure 4.11: Immunohistochemistry images (CI and CII) of tracheas from the second 
pilot study. 
Detection of collagen I (CI) or collagen II (CII) is represented in red.  CI staining was 
negative and CII staining is presented in the native cartilage and in the outer region of 
the Trilayer w/Growth Factor scaffold. 
 
 
 
146 
 
Figure 4.12: Images of the rings and tubular scaffolds for the circumferential defect 
repair. 
PCL rings, Bioglass rings, and rings encapsulated in the fibrous scaffold shown in the 
images (from top to bottom).   
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Figure 4.13: Surgical images from the circumferential defect study. 
 
Images demonstrate the removal of a portion of trachea, anchoring free trachea ends 
with sutures, comparing the scaffold to the defect site, suturing the scaffold in place, 
and the final appearance of the scaffold in the trachea. 
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Figure 4.14: Bronchoscopy images from the circumferential defect study. 
The top images were taken after tissue was excised and fixed and the bottom two 
were take in live animals.  Stenosis was observed in all cases, except for subject 1 in 
the Gradient w/Bioglass Rings group. 
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Figure 4.15: microCT images from the circumferentail defect study. 
Regions of stenosis was observed at the proximal and distal ends of the scaffold (i.e. 
at the anastomosis sites).  Different radiodensities of the ring components were due to 
the difference in material properties.  The bioactive glass rings had a high mineral 
content (e.g., calcium) thus this material is more radiodense (or radiopaque).  The 
PCL rings were polymeric materials with high carbon content thus this material is 
more radiolucent.  
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Figure 4.16: Schematic of tubular scaffolds redesign and bronchoscopy images of 
new surgical techniques on cadaver tracheas. 
After circumferential defect pilot study, the scaffold design and surgical technique 
were reevaluated.  It was determined that the scaffold should be inserted inside the 
trachea to for easier implantation and stenting of the airway at the anastomosis sites. 
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5. Chapter 5 
 
Figure 5.1: In vivo study design. 
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Figure 5.2: Surgical schematic and images. 
Surgical schematic of defect creation and scaffold implantation (a).  Photographs of 
the surgical procedure, showing induced tracheal defect and placement of scaffold (b) 
and intraoperative cell seeding (c). 
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Figure 5.3: Survival rate post-surgery. 
Chart mapping the survival rate of subjects over the course of 12 weeks. 
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Figure 5.4: Bronchoscopy images.  
Selected bronchoscopic images from each experimental group at the 4 bronchoscopic 
time points (3, 6, 9 and 12 weeks).  *Scaffold only subjects were imaged at week 3, 7, 
10, and 12.  Images follow the progression of one subject from each group.       
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Figure 5.5: Bronchoscopy scoring. 
 
Bronchoscopy image scoring based on stenosis severity, stenosis progression, type of 
stenosis, and re-epithelialization.  The bronchoscopy scoring indicated that stenosis 
progressed over time, fatality is linked to stenosis, type of narrowing is side-to-side, 
and epithelium was present in all groups.  For the stenosis severity, progression and 
re-epithelialization, data represents the averages and error bars represent one standard 
deviation.  The type of narrowing chart illustrates the number of subjects with each 
type of stenosis of the subjects experiencing stenosis.      
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Figure 5.6: Illustration of the lumen quantification process in Avizo Fire.   
The CT data was rendered into a 3D volume (trachea in yellow) (a).  The lumen space 
was thresholded and reconstructed into a 3D volume and quantified (lumen in blue) 
(b-c).  
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Figure 5.7: The area statistics from the Avizo Fire quantification. 
 
The volume was normalized to the trachea length (volume divided by length) 
resulting in a cross-sectional area.  The Scaffold Only and TGF-β3 group performed 
similarly to a native trachea.  The sample size in each group and time point were the 
following:  Scaffold-only 6 week (n=3), Scaffold-only 12 week (n=4), Scaffold-only 
AE (n=2); TGF-β3 6 week (n=3), TGF- β3 12 week (n=3), TGF- β3 AE (n=3); 
BMSC 6 week (n=4), BMSC 12 week (n=5), BMSC AE (n=1).  [# significantly 
increased area when compared to the adverse events (AE) in the same group 
(p<0.05), @ significantly increased area when compared to the BMSC-group at week 
12 (p<0.05), * significantly reduced area when compared to the native trachea 
(p<0.05)]  
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Figure 5.8: An overiew of histological images . 
Images represent all three groups at the two time points.  The scaffold is located at the 
top of the section and portions of the native trachea ring are at the bottom of the 
section.  H&E stains for cell nuclei (purple) with a pink background stain.  Alcian 
Blue stains glycosaminoglycans (GAGs) blue.  Safranin O/Fast Green stains 
proteoglycans (red) with a background of green.  Verhoeff Van-Gieson stains elastin 
(black), collagen (red), and background tissue (yellow).  Sudan Black stains polymer 
(black). 
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Figure 5.9: Magnified histological images representing scoring criteria.   
 
The types of immune cells are illustrated in the top portion of the figure.  The 
presence of new zones of cartilage and collagen are illustrated in the middle of the 
 
160 
figure.  The region of unique connective tissue inside the BMSC scaffolds are 
illustrated at the bottom of the figure. 
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Figure 5.10: Histological scoring. 
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Table 2.1: Requirements for tracheal replacement. 
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Table 2.2: Static in vitro culture studies. 
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Table 2.2 cont.: Static in vitro culture studies. 
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Table 2.3: Orthotopic in vitro culture studies. 
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Table 2.3 cont.: Orthotopic in vitro culture studies. 
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Table 2.4: Heterotopic (subcutaneous) in vivo culture studies. 
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Table 2.5: Orthotopic and subcutaneous in vivo culture studies. 
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Table 3. Chapter 3 
Table 3.1: Average fiber diameters determined with SEM. 
 
PCL fibers (PCL-only and Bilayer groups) were smaller than PLGA fibers (PLGA-
only group) at week 0 (denoted by * and ^, p=0.05). 
  
 
 
 
 
 
 
 
 
 
 
170 
Table 3.2: Overview of scaffold types and their properties.   
Scaffolds were compared to native tissue or physiological data as a benchmark for 
desired performance.  The Gradient+Rings group has the best properties, although the 
fiber diameter and porosity should be refined.   
 
 
